

OFFICIAL CODE OF GEORGIA ANNOTATED

2025 Supplement

Including Acts of the 2025 Regular
Session of the General Assembly

Prepared by

The Code Revision Commission

The Office of Legislative Counsel

and

The Editorial Staff of LexisNexis®



Published Under Authority of the State of Georgia

Volume 14B 2024 Edition

Title 16. Crimes and Offenses (Chapters 12—17)

Including Annotations to the Georgia Reports
and the Georgia Appeals Reports

**Place in Pocket of Corresponding Volume of
Main Set**

**LexisNexis®
Miamisburg, Ohio**

ISBN 978-0-327-11074-3 (set)
ISBN 978-1-66337-120-1

508711

THIS SUPPLEMENT CONTAINS

Statutes:

All laws specifically codified by the General Assembly of the State of Georgia through the 2025 Regular Session of the General Assembly.

Annotations of Judicial Decisions:

Case annotations reflecting decisions posted to LexisNexis® through May 12, 2025. These annotations will appear in the following traditional reporter sources: Georgia Reports; Georgia Appeals Reports; Southeastern Reporter; Supreme Court Reporter; Federal Reporter; Federal Supplement; Federal Rules Decisions; Lawyers' Edition; United States Reports; and Bankruptcy Reporter.

Annotations of Attorney General Opinions:

Constructions of the Official Code of Georgia Annotated, prior Codes of Georgia, Georgia Laws, the Constitution of Georgia, and the Constitution of the United States by the Attorney General of the State of Georgia posted to LexisNexis® through May 12, 2025.

Other Annotations:

References to:

Emory Bankruptcy Developments Journal.
Emory International Law Review.
Emory Law Journal.
Georgia Journal of International and Comparative Law.
Georgia Law Review.
Georgia State University Law Review.
John Marshall Law Review.
Mercer Law Review.
Georgia State Bar Journal.
Georgia Journal of Intellectual Property Law.
American Jurisprudence, Second Edition.
American Jurisprudence, Pleading and Practice Forms Annotated.
American Jurisprudence, Proof of Facts.
American Jurisprudence, Trials.
Corpus Juris Secundum.
Uniform Laws Annotated.
American Law Reports, First through Seventh Series.
American Law Reports, Federal.

Tables:

In Volume 41, a Table Eleven-A comparing provisions of the 1976 Constitution of Georgia to the 1983 Constitution of Georgia and a Table Eleven-B comparing provisions of the 1983 Constitution of Georgia to the 1976 Constitution of Georgia.

An updated version of Table Fifteen which reflects legislation through the 2025 Regular Session of the General Assembly.

Indices:

A cumulative replacement index to laws codified in the 2025 supplement pamphlets and in the bound volumes of the Code.

Contacting LexisNexis®:

Visit our internet home page at www.lexisnexis.com for an online bookstore, technical support, and other company information.

If you have questions or suggestions concerning the Official Code of Georgia Annotated, you may contact Customer Support at our self-service portal available 24/7 at supportcenter.lexisnexis.com/app/ print or call us at 800-833-9844. Direct written inquiries to:

LexisNexis®

Attn: Official Code of Georgia Annotated

9443 Springboro Pike

Miamisburg, OH 45342

TITLE 16
CRIMES AND OFFENSES
VOLUME 14

Chap.

1. General Provisions, 16-1-1 through 16-1-12.
3. Defenses to Criminal Prosecutions, 16-3-1 through 16-3-40.
5. Crimes Against the Person, 16-5-1 through 16-5-110.
6. Sexual Offenses, 16-6-1 through 16-6-25.

VOLUME 14A

7. Damage to and Intrusion upon Property, 16-7-1 through 16-7-97.
8. Offenses Involving Theft, 16-8-1 through 16-8-106.
9. Forgery and Fraudulent Practices, 16-9-1 through 16-9-157.
10. Offenses Against Public Administration, 16-10-1 through 16-10-98.
11. Offenses Against Public Order and Safety, 16-11-1 through 16-11-224.

VOLUME 14B

13. Controlled Substances, 16-13-1 through 16-13-122.
 14. Racketeer Influenced and Corrupt Organizations, 16-14-1 through 16-14-12.
-

CHAPTER 12

OFFENSES AGAINST PUBLIC HEALTH AND MORALS

ARTICLE 1

GENERAL PROVISIONS

16-12-4. Cruelty to animals.

JUDICIAL DECISIONS

Merger.

Defendant’s claim that his convictions for cruelty to animals and aggravated cruelty to animals should merge failed because the offenses were based on different acts — cruelty to animals being based on causing pain by the unjustifiable act of violently flinging the dog in the air by its

leash and aggravated cruelty to animals on maliciously torturing the dog by inflicting prolonged physical pain of starvation by shutting the dumpster lid and trapping the dog in the dumpster. *Kelley v. State*, 373 Ga. App. 1, 907 S.E.2d 217, 2024 Ga. App. LEXIS 380 (2024).

ARTICLE 3

OBSCENITY AND RELATED OFFENSES

PART 2

OFFENSES RELATED TO MINORS GENERALLY

16-12-100. Sexual exploitation of children; reporting violation; civil forfeiture; penalties.

JUDICIAL DECISIONS

ANALYSIS

JURY INSTRUCTIONS

Jury Instructions

Charge to jury.

Although the trial court did expand the definition of sexually explicit conduct beyond what was alleged in the indictment, the instruction did not likely affect the outcome of the trial or seriously affect the fairness or integrity of the proceedings because the trial court provided the jury with a copy of the indictment and instructed the jury that the burden of proof

was always upon the state and the state must produce sufficient evidence to prove each essential element of each offense beyond a reasonable doubt. It further charged the jury that they were authorized to find the defendant guilty only if they found beyond a reasonable doubt that the defendant did commit the offenses alleged in this indictment. *Smerk v. State*, 374 Ga. App. 590, 913 S.E.2d 712, 2025 Ga. App. LEXIS 95 (2025).

CHAPTER 13
CONTROLLED SUBSTANCES

Article 2		Article 3	
Regulation of Controlled Substances		Dangerous Drugs	
PART 1		Sec.	
SCHEDULES, OFFENSES, AND PENALTIES		16-13-71.	Dangerous drug.
Sec.			Article 6
16-13-25.	Schedule I.		
16-13-31.	Trafficking in cocaine, illegal drugs, marijuana, or methamphetamine; penalties.	16-13-122.	Kratom
			Content of kratom; required labeling.

ARTICLE 1
GENERAL PROVISIONS

16-13-2. Conditional discharge for possession of controlled substances as first offense and certain nonviolent property crimes; dismissal of charges; restitution to victims.

JUDICIAL DECISIONS

ANALYSIS	
EVIDENCE	
Evidence	charged offense, and not overly remote in time, and appellant's statements claiming ownership were spontaneous and not made in response to interrogation, so Miranda warnings were not required. Davis v. State, 373 Ga. App. 891, 910 S.E.2d 621, 2024 Ga. App. LEXIS 496 (2024).
Evidence sufficient to show possession. — Appellant's conviction for possession of marijuana with intent to distribute and the denial of his motion for new trial were upheld because appellant's prior drug convictions were admissible under O.C.G.A. § 24-4-404(b) as they were relevant to showing intent, similar to the	

ARTICLE 2
REGULATION OF CONTROLLED SUBSTANCES

PART 1	
SCHEDULES, OFFENSES, AND PENALTIES	
16-13-25. Schedule I.	
The controlled substances listed in this Code section are included in Schedule I:	

(1) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, pursuant to this article, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

- (A) Acetylmethadol;
- (B) Allylprodine;
- (C) Reserved;
- (D) Alphameprodine;
- (E) Alphamethadol;
- (F) Benzethidine;
- (G) Betacetylmethadol;
- (H) Betameprodine;
- (I) Betamethadol;
- (J) Betaprodine;
- (K) Brorphine;
- (L) Dextromoramide;
- (M) Dextromorphan;
- (N) Diampromide;
- (O) Diethylthiambutene;
- (P) Dimenoxadol;
- (Q) Dimetheptanol;
- (R) Dimethylthiambutene;
- (S) Dioxaphetyl butyrate;
- (T) Dipipanone;
- (U) Ethylmethylthiambutene;
- (V) Reserved;
- (W) Etoxidene;
- (X) Furethidine;
- (Y) Hydroxypethidine;
- (Z) Ketobemidone;
- (AA) Levomoramide;

- (BB) Levophenacetylmorphan;
- (CC) Morpheridine;
- (DD) Noracymethadol;
- (EE) Norlevorphanol;
- (FF) Normethadone;
- (GG) Norpipanone;
- (HH) Phenadoxone;
- (II) Phenampromide;
- (JJ) Phenomorphan;
- (KK) Phenoperidine;
- (LL) Piritramide;
- (MM) Proheptazine;
- (NN) Properidine;
- (OO) Propiram;
- (PP) Racemoramide;
- (QQ) Trimeperidine;
- (RR) 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl] benzamide (AH-7921);
- (SS) 3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide (U-47700);
- (TT) 2-methyl-AP-237;
- (UU) Tianeptine;

(2) Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (A) Acetorphine;
- (B) Acetyldihydrocodeine;
- (C) Benzylmorphine;
- (D) Codeine methylbromide;
- (E) Codeine-N-Oxide;
- (F) Cyprenorphine;

- (G) Desomorphine;
- (H) Dihydromorphine;
- (I) Etorphine;
- (J) Heroin;
- (K) Hydromorphenol;
- (L) Methyldesorphine;
- (M) Methyldihydromorphine;
- (N) Morphine methylbromide;
- (O) Morphine methylsulfonate;
- (P) Morphine-N-Oxide;
- (Q) Myrophine;
- (R) Nicocodeine;
- (S) Nicomorphine;
- (T) Normorphine;
- (U) Pholcodine;
- (V) Thebacon;

(3) Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (A) 3, 4-methylenedioxyamphetamine;
- (B) 5-methoxy-3, 4-methylenedioxyamphetamine;
- (C) 3, 4, 5-trimethoxyamphetamine;
- (D) Bufotenine;
- (E) Diethyltryptamine;
- (F) Dimethyltryptamine;
- (G) 4-methyl-2, 5-dimethoxyamphetamine;
- (H) Ibogaine;
- (I) Lysergic acid diethylamide;
- (J) Mescaline;

- (K) Peyote;
- (L) N-ethyl-3-piperidyl benzilate;
- (M) N-methyl-3-piperidyl benzilate;
- (N) Psilocybin;
- (O) Psilocyn (Psilocin);
- (P) Tetrahydrocannabinol, tetrahydrocannabinolic acid, or a combination of tetrahydrocannabinol and tetrahydrocannabinolic acid which does not contain plant material exhibiting the external morphological features of the plant of the genus *Cannabis*, but not including such substance when found in hemp or hemp products as such terms are defined in Code Section 2-23-3. Tetrahydrocannabinols do not include products approved by the federal Food and Drug Administration under Section 505 of the federal Food, Drug, and Cosmetic Act;
- (Q) 2, 5-dimethoxyamphetamine;
- (R) 4-bromo-2, 5-dimethoxyamphetamine;
- (S) 4-methoxyamphetamine;
- (T) Cyanoethylamphetamine;
- (U) (1-phenylcyclohexyl) ethylamine;
- (V) 1-(1-phenylcyclohexyl) pyrrolidine;
- (W) Phencyclidine;
- (X) 1-piperidinocyclohexanecarbonitrile;
- (Y) 1-phenyl-2-propanone (phenylacetone);
- (Z) 3, 4-Methylenedioxymethamphetamine (MDMA);
- (AA) 1-methyl-4-phenyl-4-propionoxypiperidine;
- (BB) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine;
- (CC) Acetylpsilocin (4-acetoxy-N,N-dimethyltryptamine, 4-AcO-DMT);
- (DD) N-ethyl-3, 4-methylenedioxypiperidine;
- (EE) Reserved;
- (FF) 2,5-Dimethoxy-4-Ethylamphetamine;
- (GG) Cathinone;
- (HH) Reserved;
- (II) PEPAP (1-(2-phenethyl)-4 phenyl-4-acetoxypiperide);

- (JJ) Reserved;
- (KK) Para-methoxymethamphetamine (PMMA);
- (LL) 4,4'-dimethylaminorex;
- (MM) Reserved;
- (NN) Reserved;
- (OO) 3,4-Methylenedioxy-N-Ethylamphetamine;
- (PP) 4-Methylaminorex;
- (QQ) N-Hydroxy-3,4-Methylenedioxyamphetamine;
- (RR) Reserved;
- (SS) Chlorophenylpiperazine (CPP);
- (TT) N, N-Dimethylamphetamine;
- (UU) 1-(1-(2-thienyl)cyclohexy)pyrrolidine;
- (VV) 4-Bromo-2,5-Dimethoxyphenethylamine (DMPE);
- (WW) Alpha-Ethyltryptamine;
- (XX) Methcathinone;
- (YY) Aminorex;
- (ZZ) 4-iodo-2,5-dimethoxyamphetamine;
- (AAA) 4-chloro-2,5-dimethoxyamphetamine;
- (BBB) 3,4-Methylenedioxypyrovalerone (MDPV);
- (CCC) 4-Methylmethcathinone (Mephedrone);
- (DDD) 3,4-Methylenedioxymethcathinone (Methylone);
- (EEE) 4-Methoxymethcathinone;
- (FFF) Fluoromethcathinone;
- (GGG) Fluorophenylpiperazine (FPP);
- (HHH) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- (III) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
- (JJJ) 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]- benzeneethanamine (25I-NBOMe);
- (KKK) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]- benzeneethanamine (25C-NBOMe);
- (LLL) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]- benzeneethanamine (25B-NBOMe);

- (MMM) N,N-Diallyl-5-Methoxytryptamine (5-MeO-DALT);
- (NNN) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- (OOO) 2-(2,5-Dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine (25N-NBOMe);
- (PPP) 4-acetoxy-N-ethyl-N-methyltryptamine (4-AcO-MET);
- (QQQ) 4-nitro-2,5-dimethoxyphenethylamine (2C-N);
- (RRR) 5-methoxy-N,N-methylisopropyltryptamine (5-MeO-MIPT);
- (SSS) Methoxetamine;
- (TTT) N-acetyl-3,4-methylenedioxymethcathinone;
- (UUU) 3-(1,3-benzenodioxol-5-yl)-N,2-dimethylpropan-1-amine (3,4-methylenedioxymethamphetamine methyl homolog);
- (VVV) (2-aminopropyl)-2,3-dihydrobenzofuran (APDB);
- (WWW) 4-methyl-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25D-NBOMe);
- (XXX) 2-chloro-4,5-methylenedioxymethamphetamine;
- (YYY) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
- (ZZZ) 2-bromo-4,5-methylenedioxymethamphetamine;
- (AAAA) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25H-NBOMe);
- (BBBB) Methoxyphencyclidine (MeO-PCP);
- (CCCC) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-OH-MIPT);
- (DDDD) N, α -dimethyl-5-benzofuranethanamine (5-MAPB);
- (EEEE) 1-(1-benzofuran-6-yl)propan-2-amine (6-APB);
- (FFFF) 1-(1-benzofuran-5-yl)-N-ethylpropan-2-amine (5-EAPB);
- (GGGG) Fluorophenmetrazine;
- (HHHH) 5-methoxy-N,N-Dibutyltryptamine (5-MeO-DBT);
- (IIII) 5-methoxy-N,N-Diisobutyltryptamine (5-MeO-DIBT);
- (JJJJ) N-(1,4-dimethylpentyl)-3,4-dimethoxyamphetamine;
- (KKKK) 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol (Zipeprol);

(4) Any material, compound, mixture, or preparation which contains any of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (A) Amineptine;
- (A.5) Ethylphenidate;
- (B) Fenethylline;
- (C) Mesocarb;
- (D) Methiopropamine;
- (E) Para-methoxyphenylpiperazine (MeOPP);

(5) Any material, compound, mixture, or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers, unless specifically excepted, whenever the existence of these substances, their salts, isomers, and salts of isomers is possible within the specific chemical designation:

(A) Gamma hydroxybutyric acid (gamma hydroxy butyrate); provided, however, that this does not include any amount naturally and normally occurring in the human body; and

(B) Sodium oxybate, when the FDA approved form of this drug is not:

(i) In a container labeled in compliance with subsection (a) or (b) of Code Section 26-3-8; and

(ii) In the possession of:

(I) A registrant permitted to dispense the drug;

(II) Any person other than to whom the drug was prescribed; or

(III) Any person who attempts to or does unlawfully possess, sell, distribute, or give this drug to any other person;

(6) Notwithstanding the fact that Schedule I substances have no currently accepted medical use, the General Assembly recognizes certain of these substances which are currently accepted for certain limited medical uses in treatment in the United States but have a high potential for abuse. Accordingly, unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of methaqualone, includ-

ing its salts, isomers, optical isomers, salts of their isomers, and salts of these optical isomers, is included in Schedule I;

(7) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);

(8) 1-(3-Trifluoromethylphenyl) Piperazine (TFMPP);

(9) N-Benzylpiperazine (BZP);

(10) 5-Methoxy-N,N-Diisopropyltryptamine (5-MeO-DIPT);

(11) Alpha-Methyltryptamine (AMT);

(12) Any of the following compounds, derivatives, their salts, isomers, or salts of isomers, halogen analogues, or homologues, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers, halogen analogues, or homologues is possible within the specific chemical designation:

(A) Naphthoylindoles;

(B) Naphthylmethyindoles;

(C) Naphthoylpyrroles;

(D) Naphthylideneindenes;

(E) Phenylacetylindoles;

(F) Cyclohexylphenols;

(G) Benzoylindoles;

(H) Tricyclic benzopyrans;

(I) Adamantoylindoles;

(J) Indazole amides;

(K) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN 55,212-2);

(L) Any compound, unless specifically excepted or listed in this or another schedule, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:

(i) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substitutions, whether or not further substituted in the ring system;

(ii) By substitution at the 3-position with an alkyl, alkoxy, or cyclic substitution;

(iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, cyclohexyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure;

(M) Indole carboxamides;

(N) Indole carboxylates;

(O) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester (URB602);

(P) Indazole carboxylates;

(Q) [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB597);

(R) 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one (URB754);

(S) Indole tetramethylcyclopropanecarbonyls;

(T) Naphthoylbenzimidazoles;

(U) 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone (CB-13);

(V) Naphthoylindazoles;

(W) Azaindole carboxamide;

(13) The fentanyl analog structural class, including any of the following derivatives, their salts, isomers, or salts of isomers, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from fentanyl, and whether or not further modified in any of the following ways:

(A) Substitution anywhere on the phenethyl group with:

(i) Alkyl group;

(ii) Hydroxyl group;

(iii) Halide group;

(B) Replacement of the phenethyl group with:

- (i) Thienyl ethyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (ii) Oxotetrazol ethyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (iii) Alkyl group;
- (iv) Thienyl methyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (v) Benzyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (vi) Furanyl ethyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (vii) Phenyl alkyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (viii) Pyridinyl ethyl group, which can be further substituted with:
 - (I) Alkyl group;

- (II) Hydroxyl group;
- (III) Halide group;
- (ix) Diazole ethyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
 - (IV) Nitro group;
- (x) Thiazole ethyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (xi) Benzoxazolinone ethyl group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
- (C) Substitution anywhere on the piperidine ring with:
 - (i) Alkyl group;
 - (ii) Allyl group;
 - (iii) Phenyl group;
 - (iv) Ester group;
 - (v) Ether group;
 - (vi) Pyridine group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
 - (vii) Thiazole group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;

- (viii) Oxadiazole group, which can be further substituted with:
 - (I) Alkyl group;
 - (II) Hydroxyl group;
 - (III) Halide group;
 - (IV) Ether group;
- (D) Substitution anywhere on the propanamide group with:
 - (i) Cyclic alkyl group;
 - (ii) Acyclic alkyl group;
 - (iii) Methoxy group;
- (E) Replacement of the propanamide group with:
 - (i) Acryloyl amino group;
 - (ii) Acetamide group, which itself can be further substituted with:
 - (I) Cyclic alkyl group;
 - (II) Tetrahydrofuran group;
 - (III) Tetrahydrothiophene group;
 - (iii) Methoxy acetamide group;
 - (iv) Furanyl amide group;
 - (v) Amine;
- (F) Substitution anywhere on the phenyl ring with:
 - (i) Halide group;
 - (ii) Methoxy group;
 - (iii) Alkyl group;
- (G) Replacement of the phenyl ring with the pyrazine ring;

(14) The piperidinyl-sulfonamide structural class, including any of the following compounds, derivatives, their salts, isomers, or salts of isomers, halogen analogues, or homologues, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers, halogen analogues, or homologues is possible within the specific chemical designation or unless specifically excepted or listed in this or another

schedule, structurally derived from piperidiny-sulfonamide, and whether or not further modified in any of the following ways:

(A) By substitution at the 1-position of the piperidiny ring with any of the following:

- (i) Alkyl group;
- (ii) Phenyl alkyl group;
- (iii) Amino substituted phenyl alkyl group;
- (iv) Nitro substituted phenyl alkyl group;
- (v) Cycloalkyl group;
- (vi) Alkenyl substituent group;

(B) By substitution at the 3-position or 4-position of the piperidiny ring with any of the following:

- (i) Halide group;
- (ii) Alkyl group;
- (iii) Alkoxy substituent;

(C) By substitution on the sulfonamide with any of the following:

- (i) Pyridyl group;
- (ii) Alkyl group;
- (iii) Phenyl group;
- (iv) Phenyl alkyl group;
- (v) Alkoxy substituted phenyl group;
- (vi) Halogen substituted phenyl group;
- (vii) Nitro substituted phenyl group;
- (viii) Amino substituted phenyl group;
- (ix) Alkanoylamino substituted phenyl group;
- (x) Amido substituted phenyl group;

(15) The 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45) structural class, including any of the following derivatives, their salts, isomers, or salts of isomers, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical

designation or unless specifically excepted or listed in this or another schedule, structurally derived from 1-cyclohexyl-4-(1,2- diphenylethyl)-piperazine (MT-45), and whether or not further modified in any of the following ways:

(A) Replacement of the cyclohexyl group with any of the following:

- (i) Cycloheptyl group;
- (ii) Cyclooctyl group;

(B) Substitution on the diphenyl groups with any of the following:

- (i) Hydroxyl group;
- (ii) Halide;
- (iii) Alkoxy group;
- (iv) Alkyl group;
- (v) Ester group;
- (vi) Phenyl ether group;

(16) The N-substituted benzimidazole structural class, including any of the following derivatives, their salts, isomers, or salts of isomers unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from N-substituted benzimidazole by substitution at the 1-position with an ethylamine group and by substitution at the 2-position with a benzyl group, whether or not the compound is further modified in any of the following ways:

(A) By monoalkyl or dialkyl substitution on the nitrogen of the 1-position ethylamine group, or by inclusion of the nitrogen in a cyclic structure;

(B) By substitution on the benzylic carbon of the 2-position benzyl group by alkyl or carboxamide groups;

(C) By substitution at the 3-position or 4-position of the benzyl group, or both, with alkyl, hydroxyl, alkoxy, acetoxy, halide, or sulfide groups;

(D) By replacement of the 2-position benzyl group with an ethylbenzyl, thiophenol, or methoxybenzene group, which may be

further substituted with alkyl, hydroxyl, alkoxy, acetoxy, halide, or sulfide groups; and

(E) By substitution at the 5-position or 6-position with a nitro group or primary amine;

(17) Clonazepam;

(18) Cumyl-pegacalone;

(19) Diclazepam;

(20) Etizolam;

(21) Flualprazolam;

(22) Flubromazolam.

History.

Code 1933, § 79A-806, enacted by Ga. L. 1974, p. 221, § 1; Ga. L. 1978, p. 1668, § 6; Ga. L. 1979, p. 859, § 5; Ga. L. 1980, p. 1746, § 4; Ga. L. 1981, p. 557, § 3; Ga. L. 1982, p. 2403, §§ 11, 16; Ga. L. 1984, p. 22, § 16; Ga. L. 1984, p. 1019, § 1; Ga. L. 1985, p. 1219, § 2; Ga. L. 1986, p. 1555, § 3; Ga. L. 1987, p. 261, § 1; Ga. L. 1989, p. 233, § 1; Ga. L. 1990, p. 8, § 16; Ga. L. 1990, p. 640, § 1; Ga. L. 1992, p. 1131, § 1; Ga. L. 1994, p. 169, §§ 1–3, 3.1; Ga. L. 1996, p. 356, § 1; Ga. L. 2001, p. 816, § 1; Ga. L. 2002, p. 415, § 16; Ga. L. 2003, p. 349, § 2; Ga. L. 2005, p. 1028, § 1/SB 89; Ga. L. 2006, p. 219, § 14/HB 1054; Ga. L. 2008, p. 169, §§ 1, 2/HB 1090; Ga. L. 2010, p. 338, § 1/HB 1309; Ga. L. 2010, p. 860, § 1/SB 353; Ga. L. 2011, p. 656, §§ 1, 2/SB 93; Ga. L. 2012, p. 40, §§ 2, 3/SB 370; Ga. L. 2013, p. 5, § 1/HB 57; Ga. L. 2013, p. 71, §§ 1, 1.1/HB 302; Ga. L. 2013, p. 141, § 16/HB 79; Ga. L. 2014, p. 217,

§§ 1-3/HB 835; Ga. L. 2015, p. 883, §§ 1, 2/HB 211; Ga. L. 2016, p. 798, §§ 2, 3/HB 783; Ga. L. 2017, p. 14, §§ 1-4/HB 231; Ga. L. 2017, p. 417, §§ 7-1, 7-2/SB 104; Ga. L. 2018, p. 314, §§ 1-4/HB 830; Ga. L. 2018, p. 1112, § 16/SB 365; Ga. L. 2019, p. 820, § 1/HB 483; Ga. L. 2019, p. 1030, § 3/HB 213; Ga. L. 2021, p. 184, § 26/SB 195; Ga. L. 2021, p. 386, §§ 1-4/HB 367; Ga. L. 2022, p. 803, §§ 1–5/HB 963; Ga. L. 2023, p. 137, §§ 1, 2/HB 332, effective May 1, 2023; Ga. L. 2024, p. 161, §§ 1–3/HB 1326, effective April 22, 2024; Ga. L. 2025, p. 200, §§ 1–4/HB 473, effective May 1, 2025.

Amendments.

The 2025 amendment, effective May 1, 2025, substituted “2-methyl-AP-237” for “Methyl-AP-237” in subparagraph (1)(TT); substituted the present provisions of subparagraph (3)(CC) for the former provisions, which read: “Reserved;”; added subparagraph (4)(A.5), and added subdivision (13)(E)(ii)(III).

16-13-30. Purchase, possession, manufacture, distribution, or sale of controlled substances or marijuana; penalties.

JUDICIAL DECISIONS

ANALYSIS

POSSESSION

Possession

State proved possession of marijuana. — Appellant’s conviction for pos-

session of marijuana with intent to distribute and the denial of his motion for new trial were upheld because appellant’s

prior drug convictions were admissible under O.C.G.A. § 24-4-404(b) as they were relevant to showing intent, similar to the charged offense, and not overly remote in time, and appellant's statements claiming ownership were spontaneous and not made in response to interrogation, so Miranda warnings were not required. *Davis v. State*, 373 Ga. App. 891, 910 S.E.2d 621, 2024 Ga. App. LEXIS 496 (2024).

Evidence sufficient for conviction.

Circumstantial evidence, including the defendant hiding the pills with other contraband and driving in a restricted area used for dropping contraband, was sufficient for the jury to find the defendant possessed oxycodone beyond a reasonable doubt. *Hutchins v. State*, 374 Ga. App. 289, 912 S.E.2d 164, 2025 Ga. App. LEXIS 39 (2025).

16-13-31. Trafficking in cocaine, illegal drugs, marijuana, or methamphetamine; penalties.

(a)(1) Except as authorized by this article, any person who sells, manufactures, delivers, or brings into this state or who is in possession of 28 grams or more of cocaine or of any mixture with a purity of 10 percent or more of cocaine, as described in Schedule II, in violation of this article commits the felony offense of trafficking in cocaine and, upon conviction thereof, shall be punished as follows:

(A) If the quantity of the cocaine or the mixture involved is 28 grams or more, but less than 200 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of ten years and shall pay a fine of \$200,000.00;

(B) If the quantity of the cocaine or the mixture involved is 200 grams or more, but less than 400 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of 15 years and shall pay a fine of \$300,000.00; and

(C) If the quantity of the cocaine or the mixture involved is 400 grams or more, the person shall be sentenced to a mandatory minimum term of imprisonment of 25 years and shall pay a fine of \$1 million.

(2) Except as authorized by this article, any person who sells, manufactures, delivers, or brings into this state or who is in possession of any mixture with a purity of less than 10 percent of cocaine, as described in Schedule II, in violation of this article commits the felony offense of trafficking in cocaine if the total weight of the mixture multiplied by the percentage of cocaine contained in the mixture exceeds any of the quantities of cocaine specified in paragraph (1) of this subsection. Upon conviction thereof, such person shall be punished as provided in paragraph (1) of this subsection, depending upon the quantity of cocaine such person is charged with selling, manufacturing, delivering, or bringing into this state or possessing.

(b) Except as authorized by this article, any person who sells,

manufactures, delivers, brings into this state, or has possession of four grams or more of any morphine, opium, or substance identified in subparagraph (RR) or (SS) of paragraph (1) or paragraph (14) or (15) of Code Section 16-13-25, or subparagraph (A), (C.5), (U.1), (V), or (V.2) of paragraph (2) of Code Section 16-13-26 or any salt, isomer, or salt of an isomer thereof, including heroin, as described in Schedules I and II, or four grams or more of any mixture containing any such substance in violation of this article commits the felony offense of trafficking in illegal drugs and, upon conviction thereof, shall be punished as follows:

(1) If the quantity of such substances involved is four grams or more, but less than 14 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of five years and shall pay a fine of \$50,000.00;

(2) If the quantity of such substances involved is 14 grams or more, but less than 28 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of ten years and shall pay a fine of \$100,000.00; and

(3) If the quantity of such substances involved is 28 grams or more, the person shall be sentenced to a mandatory minimum term of imprisonment of 25 years and shall pay a fine of \$500,000.00.

(b.1) Except as authorized by this article, any person who sells, manufactures, delivers, brings into this state, or has possession of fentanyl as identified in subparagraph (F) of paragraph (2) of Code Section 16-13-26, the fentanyl analog structural class as identified in paragraph (13) of Code Section 16-13-25, or any mixture containing any such substance in violation of this article commits the felony offense of trafficking in fentanyl and, upon conviction thereof, shall be punished as follows:

(1) If the quantity of such substances involved is four grams or more, but less than eight grams, the person shall be sentenced to a mandatory minimum term of imprisonment of ten years and shall pay a fine of \$75,000.00;

(2) If the quantity of such substances involved is eight grams or more, but less than 14 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of 15 years and shall pay a fine of \$150,000.00;

(3) If the quantity of such substances involved is 14 grams or more, but less than 28 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of 25 years and shall pay a fine of \$250,000.00; and

(4) If the quantity of such substances involved is 28 grams or more, the person shall be sentenced to a mandatory minimum term of imprisonment of 35 years and shall pay a fine of \$750,000.00.

(c) Except as authorized by this article, any person who sells, manufactures, grows, delivers, brings into this state, or has possession of a quantity of marijuana exceeding ten pounds commits the offense of trafficking in marijuana and, upon conviction thereof, shall be punished as follows:

(1) If the quantity of marijuana involved is in excess of ten pounds, but less than 2,000 pounds, the person shall be sentenced to a mandatory minimum term of imprisonment of five years and shall pay a fine of \$100,000.00;

(2) If the quantity of marijuana involved is 2,000 pounds or more, but less than 10,000 pounds, the person shall be sentenced to a mandatory minimum term of imprisonment of seven years and shall pay a fine of \$250,000.00; and

(3) If the quantity of marijuana involved is 10,000 pounds or more, the person shall be sentenced to a mandatory minimum term of imprisonment of 15 years and shall pay a fine of \$1 million.

(d) Except as authorized by this article, any person who sells, manufactures, delivers, or brings into this state 200 grams or more of methaqualone or of any mixture containing methaqualone, as described in paragraph (6) of Code Section 16-13-25, in violation of this article commits the felony offense of trafficking in methaqualone and, upon conviction thereof, shall be punished as follows:

(1) If the quantity of the methaqualone or the mixture involved is 200 grams or more, but less than 400 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of five years and shall pay a fine of \$50,000.00; and

(2) If the quantity of the methaqualone or the mixture involved is 400 grams or more, the person shall be sentenced to a mandatory minimum term of imprisonment of 15 years and shall pay a fine of \$250,000.00.

(e) Except as authorized by this article, any person who sells, delivers, or brings into this state or has possession of 28 grams or more of methamphetamine, amphetamine, or any mixture containing either methamphetamine or amphetamine, as described in Schedule II, in violation of this article commits the felony offense of trafficking in methamphetamine or amphetamine and, upon conviction thereof, shall be punished as follows:

(1) If the quantity of methamphetamine, amphetamine, or a mixture containing either substance involved is 28 grams or more, but less than 200 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of ten years and shall pay a fine of \$200,000.00;

(2) If the quantity of methamphetamine, amphetamine, or a mixture containing either substance involved is 200 grams or more, but less than 400 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of 15 years and shall pay a fine of \$300,000.00; and

(3) If the quantity of methamphetamine, amphetamine, or a mixture containing either substance involved is 400 grams or more, the person shall be sentenced to a mandatory minimum term of imprisonment of 25 years and shall pay a fine of \$1 million.

(f) Except as authorized by this article, any person who manufactures methamphetamine, amphetamine, or any mixture containing either methamphetamine or amphetamine, as described in Schedule II, in violation of this article commits the felony offense of trafficking methamphetamine or amphetamine and, upon conviction thereof, shall be punished as follows:

(1) If the quantity of methamphetamine, amphetamine, or a mixture containing either substance involved is less than 200 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of ten years and shall pay a fine of \$200,000.00;

(2) If the quantity of methamphetamine, amphetamine, or a mixture containing either substance involved is 200 grams or more, but less than 400 grams, the person shall be sentenced to a mandatory minimum term of imprisonment of 15 years and shall pay a fine of \$300,000.00; and

(3) If the quantity of methamphetamine, amphetamine, or a mixture containing either substance involved is 400 grams or more, the person shall be sentenced to a mandatory minimum term of imprisonment of 25 years and shall pay a fine of \$1 million.

(g)(1) The district attorney may move the sentencing court to impose a reduced or suspended sentence upon any person who is convicted of a violation of this Code section who provides substantial assistance in the identification, arrest, or conviction of any of his or her accomplices, accessories, coconspirators, or principals. Upon good cause shown, the motion may be filed and heard in camera. Upon hearing such motion, the sentencing court may impose a reduced or suspended sentence if such court finds that the defendant has rendered such substantial assistance.

(2)(A) The sentencing court may, in its discretion, depart from the mandatory minimum sentence specified for a person who is convicted of a violation of this Code section as set forth in subparagraph (B) of this paragraph if such court concludes that:

(i) The defendant was not a leader of the criminal conduct;

(ii) The defendant did not possess or use a firearm, dangerous weapon, or hazardous object during the crime;

(iii) The criminal conduct did not result in a death or serious bodily injury to a person other than to a person who is a party to the crime;

(iv) The defendant has no prior felony conviction; and

(v) The interests of justice will not be served by the imposition of the prescribed mandatory minimum sentence.

(B) The sentencing departure ranges pursuant to subparagraph (A) of this paragraph shall be as follows:

(i) Any person convicted of violating subparagraph (a)(1)(A), paragraph (2) of subsection (a) relating to the quantity of drugs specified in subparagraph (a)(1)(A) of this Code section, or paragraph (1) of subsection (e) or (f) of this Code section, imprisonment for not less than five nor more than ten years and a fine of not less than \$100,000.00 nor more than \$200,000.00;

(ii) Any person convicted of violating subparagraph (a)(1)(B), paragraph (2) of subsection (a) relating to the quantity of drugs specified in subparagraph (a)(1)(B) of this Code section, or paragraph (2) of subsection (e) or (f) of this Code section, imprisonment for not less than seven years and six months nor more than 15 years and a fine of not less than \$150,000.00 nor more than \$300,000.00;

(iii) Any person convicted of violating subparagraph (a)(1)(C), paragraph (2) of subsection (a) relating to the quantity of drugs specified in subparagraph (a)(1)(C) of this Code section, or paragraph (3) of subsection (e) or (f) of this Code section, imprisonment for not less than 12 years and six months nor more than 25 years and a fine of not less than \$500,000.00 nor more than \$1 million;

(iv) Any person convicted of violating paragraph (1) of subsection (b) or (d) of this Code section, imprisonment for not less than two years and six months nor more than five years and a fine of not less than \$25,000.00 nor more than \$50,000.00;

(v) Any person convicted of violating paragraph (2) of subsection (b) of this Code section, imprisonment for not less than five years nor more than ten years and a fine of not less than \$50,000.00 nor more than \$100,000.00;

(vi) Any person convicted of violating paragraph (3) of subsection (b) of this Code section, imprisonment for not less than 12

years and six months nor more than 25 years and a fine of not less than \$250,000.00 nor more than \$500,000.00;

(vii) Any person convicted of violating paragraph (1) of subsection (b.1) of this Code section, imprisonment for not less than two years and six months nor more than five years and a fine of not less than \$12,500.00 nor more than \$25,000.00;

(viii) Any person convicted of violating paragraph (2) of subsection (b.1) of this Code section, imprisonment for not less than five years nor more than ten years and a fine of not less than \$25,000.00 nor more than \$50,000.00;

(ix) Any person convicted of violating paragraph (3) of subsection (b.1) of this Code section, imprisonment for not less than ten years nor more than 20 years and a fine of not less than \$50,000.00 nor more than \$100,000.00;

(x) Any person convicted of violating paragraph (4) of subsection (b.1) of this Code section, imprisonment for not less than 15 years nor more than 30 years and a fine of not less than \$250,000.00 nor more than \$500,000.00;

(xi) Any person convicted of violating paragraph (1) of subsection (c) of this Code section, imprisonment for not less than two years and six months nor more than five years and a fine of not less than \$50,000.00 nor more than \$100,000.00;

(xii) Any person convicted of violating paragraph (2) of subsection (c) of this Code section, imprisonment for not less than three years and six months nor more than seven years and a fine of not less than \$125,000.00 nor more than \$250,000.00;

(xiii) Any person convicted of violating paragraph (3) of subsection (c) of this Code section, imprisonment for not less than seven years and six months nor more than 15 years and a fine of not less than \$500,000.00 nor more than \$1 million; and

(xiv) Any person convicted of violating paragraph (2) of subsection (d) of this Code section, imprisonment for not less than seven years and six months nor more than 15 years and a fine of not less than \$125,000.00 nor more than \$250,000.00.

(C) If the sentencing court departs from the mandatory minimum sentence pursuant to this paragraph, such court shall specify on the record the circumstances for such departure and the interests served by such departure. Any such order shall be appealable by the State of Georgia pursuant to Code Section 5-7-1.

(D) As used in this paragraph, the term:

(i) “Dangerous weapon” shall have the same meaning as set forth in Code Section 16-11-121.

(ii) “Firearm” shall have the same meaning as set forth in Code Section 16-11-131.

(iii) “Hazardous object” shall have the same meaning as set forth in Code Section 20-2-751.

(iv) “Leader” means a person who planned and organized others and acted as a guiding force in order to achieve a common goal.

(3) The sentencing court may, in its discretion, depart from the mandatory minimum sentence specified in this Code section for a person who is convicted of a violation of this Code section when the prosecuting attorney and the defendant have agreed to a sentence that is below such mandatory minimum.

(h) Any person who violates any provision of this Code section shall be punished as provided for in the applicable mandatory minimum punishment and for not more than 30 years of imprisonment and by a fine not to exceed \$1 million.

(i) Except as provided in subsection (g) of this Code section and notwithstanding the provisions of Code Section 16-13-2 to the contrary, with respect to any person who is found to have violated this Code section, no portion of the mandatory minimum sentence shall be suspended, stayed, probated, deferred, or otherwise withheld by the sentencing court. Any sentence imposed pursuant to subsection (g) of this Code section shall not be reduced by any earned time, early release, work release, leave, or other sentence-reducing measures under programs administered by the Department of Corrections, the effect of which would be to reduce the period of incarceration ordered by the sentencing court or any form of pardon, parole, or commutation of sentence by the State Board of Pardons and Paroles; provided, however, that during the final year of incarceration, a defendant so sentenced shall be eligible to be considered for participation in a Department of Corrections administered transitional center or work release program.

History.

Ga. L. 1980, p. 432, § 1; Ga. L. 1982, p. 3, § 16; Ga. L. 1982, p. 2215, § 1; Ga. L. 1983, p. 620, § 1; Ga. L. 1985, p. 149, § 16; Ga. L. 1985, p. 552, § 1; Ga. L. 1986, p. 10, § 16; Ga. L. 1986, p. 397, § 1; Ga. L. 1988, p. 420, § 2; Ga. L. 1989, p. 1594, § 1; Ga. L. 1992, p. 2106, § 1; Ga. L. 1994, p. 169, § 5.1; Ga. L. 1997, p. 1311, § 5; Ga. L. 2003, p. 177, § 4; Ga. L. 2003, p. 257, § 1; Ga. L. 2012, p. 899, § 3-8/HB

1176; Ga. L. 2013, p. 222, § 4/HB 349; Ga. L. 2014, p. 432, § 2-8/HB 826; Ga. L. 2014, p. 780, § 2-2/SB 364; Ga. L. 2015, p. 5, § 16/HB 90; Ga. L. 2017, p. 417, § 6-2/SB 104; Ga. L. 2025, p. 460, § 1-2/SB 79, effective July 1, 2025.

Amendments.

The 2025 amendment, effective July 1, 2025, in subsection (b), substituted “paragraph (14) or (15) of Code Section 16-13-25, or subparagraph (A), (C.5),

(U.1)” for “paragraph (13), (14), or (15) of Code Section 16-13-25, or subparagraph (A), (C.5), (F), (U.1)”;

added subsection (b.1); in subsection (g), substituted “Upon hearing such motion, the sentencing court may” for “The judge hearing the motion may” in the third sentence and substituted “such court” for “he or she” in paragraph (g)(1); substituted “The sentencing court may, in its discretion, depart” for “In the court’s discretion, the judge may depart” and substituted “such court” for “the judge” in subparagraph (g)(2)(A); rewrote subparagraph (g)(2)(B); in subparagraph (g)(2)(C), substituted “If the sentencing court departs from the mandatory” for “If a judge reduces the mandatory”, substituted “such court” for “the judge”, and substituted “such departure” for “the reduction” in the first sentence; in division (g)(2)(D)(ii), substituted “Code Section 16-11-131” for “Code Section 16-11-127.1” at the end; in paragraph (g)(3), substituted “The sentencing court may, in its discretion, depart” for “In the court’s discretion,

the judge may depart” at the beginning; and, in subsection (i), substituted “Except as provided in subsection (g) of this Code section and notwithstanding the provisions of Code Section 16-13-2 to the contrary, with respect to any person who is found to have violated this Code section, no portion of the mandatory minimum sentence shall be suspended, stayed, probated, deferred, or otherwise withheld by the sentencing court. Any sentence” for “Notwithstanding Code Section 16-13-2, any sentence” at the beginning.

Editor’s notes.

Ga. L. 2025, p. 460, § 1-1/SB 79, not codified by the General Assembly, provides: “This Act shall be known and may be cited as the Fentanyl Eradication and Removal Act.”

Ga. L. 2025, p. 460, § 3-1/SB 79, not codified by the General Assembly, provides that the 2025 amendment shall be applicable to all offenses committed on or after July 1, 2025.

JUDICIAL DECISIONS

ANALYSIS

SUFFICIENCY OF EVIDENCE
METHAMPHETAMINE OR AMPHETAMINE
3. EVIDENCE
5. SENTENCING

Sufficiency of Evidence

Evidence sufficient to support trafficking in methamphetamine conviction.

Evidence including the confidential informant’s testimony that the informant arranged a methamphetamine sale with the defendant, the defendant drove up and parked next to the informant in the arranged location, and the defendant got into the informant’s car with the drugs that were later seized was sufficient to support the defendant’s conviction for trafficking in methamphetamine. *Ashley v. State*, 374 Ga. App. 153, 911 S.E.2d 701, 2025 Ga. App. LEXIS 16 (2025).

Methamphetamine or Amphetamine

3. Evidence

Circumstantial evidence sufficient to support conviction of possession of methamphetamine.

Trial court correctly based the court’s revocation decision of defendant’s probation on the court’s determination that defendant committed the new offenses of trafficking methamphetamine and possessing drug-related objects based on state showing by a preponderance of the drug evidence, the field test, and officer testimony. *Alexander v. State*, 371 Ga. App. 532, 901 S.E.2d 584, 2024 Ga. App. LEXIS 181 (2024).

5. Sentencing

Trial court required to impose maximum recidivist sentence. — Following defendant pleading guilty to trafficking over 400 grams of methamphetamine and possession of a firearm by a convicted felon, the trial court erred by

not sentencing defendant to a maximum 30 years as a recidivist under O.C.G.A. § 17-10-7(a) but retained discretion under O.C.G.A. § 17-10-1(a)(1)(A) to probate part of the sentence. *State v. Roundtree*, 372 Ga. App. 518, 904 S.E.2d 694, 2024 Ga. App. LEXIS 319 (2024).

ARTICLE 3

DANGEROUS DRUGS

16-13-71. Dangerous drug.

(a) A “dangerous drug” means any drug other than a drug contained in any schedule of Article 2 of this chapter, which, under the federal Food, Drug, and Cosmetic Act (52 Stat. 1040 (1938)), 21 U.S.C. Section 301, et seq., as amended, may be dispensed only upon prescription. In any civil or criminal action or other proceedings, a certification from the Food and Drug Administration of the United States Department of Health and Human Services attesting to the fact that a drug other than a drug contained in any schedule of Article 2 of this chapter involved in the action or proceeding is a dangerous drug that federal law prohibits dispensing of without a prescription pursuant to the federal Food, Drug, and Cosmetic Act shall be admissible as prima-facie proof that such drug is a “dangerous drug.”

(b) In addition to subsection (a) of this Code section, a “dangerous drug” means any other drug or substance declared by the General Assembly to be a dangerous drug; to include any of the following drugs, chemicals, or substances; salts, isomers, esters, ethers, or derivatives of such drugs, chemicals, or substances which have essentially the same pharmacological action; all other salts, isomers, esters, ethers, and compounds of such drugs, chemicals, or substances unless specifically exempted and the following devices, identified as “dangerous drugs”:

- (.03) Abacavir;
- (.031) Abaloparatide;
- (.033) Abametapir;
- (.035) Abarelis;
- (.037) Abatacept;
- (.04) Abciximab;
- (.041) Abemaciclib;
- (.042) Abiraterone;

- (.043) AbobotulinumtoxinA;
- (.0435) Abrocitinib;
- (.044) Acalabrutinib;
- (.045) Acamprostate;
- (.05) Acarbose;
- (.1) Acebutolol;
- (1) Acecarbromal;
- (2) Acenocoumarol;
- (3) Acetazolamide;
- (3.5) Reserved;
- (4) Acetohexamide;
- (4.1) Aceto-hydroxamic acid;
- (5) Acetophenazine;
- (6) Acetosulfone;
- (7) Acetyl sulfamethoxypyridazine;
- (8) Acetyl sulfisoxazole;
- (9) Acetylcarbromal;
- (10) Acetylcholine;
- (11) Acetylcysteine;
- (12) Acetyldigoxin;
- (12.1) Acitretin;
- (12.5) Aclidinium bromide;
- (12.8) Acoramidis;
- (13) Acrisorcin;
- (13.3) Acrivastine;
- (13.5) Acyclovir;
- (13.52) Adagrasib;
- (13.53) Adalimumab;
- (13.531) Adalimumab-atto;
- (13.54) Adamts13, recombinant-krhn;
- (13.55) Adapalene — See exceptions;

- (13.6) Adenosine;
- (14) Adenosine 5-monophosphate;
- (14.5) Adenovirus;
- (15) Adenylic acid;
- (16) Adiphenine hydrochloride;
- (16.5) Ado-trastuzumab;
- (17) Adrenal cortex extracts;
- (17.03) Aducanumab-avwa;
- (17.05) Afamelanotide;
- (17.07) Afamitresgene autoleucel;
- (17.1) Afatinib;
- (17.3) Aflibercept;
- (17.4) Air polymer-type A;
- (17.5) Albendazole;
- (17.6) Albiglutide;
- (17.7) Albiraterone;
- (18) Albumin, normal human serum;
- (18.1) Albuterol;
- (19) Albutonium;
- (19.3) Alcaftadine — See exceptions;
- (19.5) Alclometasone dipropionate;
- (19.57) Alectinib;
- (19.58) Alemtuzumab;
- (19.6) Alendronate;
- (19.65) Alfuzosin;
- (19.7) Alglucerase;
- (19.75) Alglucosidase alfa;
- (19.76) Alirocumab;
- (19.77) Aliskiren;
- (19.8) Alitretinoin;
- (20) Alkaverir;

- (21) Alkavervir;
- (21.1) Alkyl nitrites;
- (21.3) Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat;
- (21.5) Allogeneic processed thymus tissue-agdc;
- (22) Allopurinol;
- (22.2) Almotriptan;
- (22.3) Alogliptin;
- (22.5) Alosetron;
- (22.7) Alpelisib;
- (23) Alpha amylase;
- (23.1) Alprostadil;
- (24) Alseroxylon;
- (24.1) Altenodol;
- (24.6) Altretamine;
- (25) Aluminum nicotinate;
- (26) Alverine;
- (26.5) Alvimopan;
- (27) Amantadine;
- (28) Ambenonium chloride;
- (28.5) Ambrisentan;
- (29) Ambrosiacaе follens;
- (30) Amcinonide;
- (30.1) Amdinocillin;
- (30.4) Amifampridine;
- (30.5) Amifostine;
- (31) Amikacin;
- (31.1) Amiloride;
- (32) Aminacrine;
- (33) 4-amino-N-methyl-pteroylglutamic acid;
- (34) Amino acid preparations for injection or vaginal use;

- (35) Aminocaproic acid;
- (36) Aminohippurate;
- (36.5) Aminolevulinic acid;
- (37) Aminophylline;
- (38) Aminosalicylate — See exceptions;
- (39) Aminosalicylate calcium — See exceptions;
- (40) Aminosalicylate potassium — See exceptions;
- (41) Aminosalicylate sodium — See exceptions;
- (42) Aminosalicylic acid — See exceptions;
- (42.1) Amiodarone;
- (43) Amisometradine;
- (43.5) Amisulpride;
- (44) Amitriptyline;
- (44.1) Amivantamab-vmjw;
- (44.3) Amlexanox;
- (44.5) Amlodipine;
- (44.6) Ammonia, N-13;
- (44.7) Ammonium lactate;
- (45) Amodiaquin;
- (45.5) Amoxapine;
- (46) Amoxicillin;
- (47) Amphotericin B;
- (48) Ampicillin;
- (48.2) Amprenavir;
- (48.6) Amrinone;
- (49) Amyl nitrite;
- (50) Amylolytic enzymes;
- (50.1) Anabolic steroids, if listed in Code Section 16-13-27.1 as being exempt as Schedule III controlled substances;
- (50.2) Anacaulase-bcdb;
- (50.3) Anagrelide;

(50.4) Anakinra;

(50.5) Anastrozole;

(51) Androgens, except those androgens listed in paragraph (6) of Code Section 16-13-27;

(51.5) Angiotensin II;

(52) Angiotensin amide;

(52.5) Anidulafungin;

(52.7) Anifrolumab-fnia;

(53) Anisindione;

(54) Anisotropine;

(54.5) Ansuvimab-zykl;

(55) Antazoline;

(56) Anterior pituitary hormones;

(57) Anthralin;

(57.5) Anthrax vaccine adsorbed, Adjuvanted;

(58) Anti-coagulant acid:

(A) Citrate dextrose;

(58.5) Anticoagulant sodium citrate 4 percent solution;

(59) Antigens:

(A) *Alternaria tenius*;

(B) Aqua ivy;

(C) Ash mix;

(D) *Aspergillus fumigatus*;

(E) Bacterial, *Staphylococcus aureus*, Type 1;

(F) Bacterial, *Staphylococcus aureus*, Type 3;

(G) Bacterial, Undenatured;

(H) Bee;

(I) Beech;

(J) Bermuda grass;

(K) Birch;

(L) California live oak;

- (M) *Candida albicans*;
- (N) Careless weed;
- (O) Cat epithelia;
- (P) Cattle epithelia;
- (Q) *Coccidioides immitis*;
- (R) Cottonwood fremont;
- (S) Dog epithelia;
- (T) Elm mix;
- (U) English plantain;
- (V) Feather mix;
- (W) Gram negative bacterial;
- (X) *Helminthosporium sativum*;
- (Y) Hickory;
- (Z) *Hormodendrum hordei*;
- (AA) Hornet;
- (BB) House dust;
- (BB.5) House dust mite allergen extract;
- (CC) House dust mix;
- (DD) Insects;
- (EE) Intradermal or scratching test;
- (FF) Johnson grass;
- (GG) Kentucky blue grass;
- (HH) Kochia;
- (II) Lamb quarters;
- (JJ) Maple;
- (KK) Mesquite;
- (LL) Mixed epidermals;
- (MM) Mixed grass, ragweeds (spring-fall);
- (NN) Mixed grasses (spring);
- (OO) Mixed inhalants;
- (PP) Mixed molds;

- (QQ) Mixed ragweed;
- (RR) Mixed ragweed — mixed weeds (fall);
- (SS) Mixed weeds;
- (TT) Molds;
- (UU) Mountain cedar;
- (VV) Mugwort common;
- (WW) National weed mix;
- (XX) Oak mix;
- (YY) Olive;
- (ZZ) Orchard grass;
- (ZZ.5) Peanut (*arachis hypogaea*) allergen powder-dnfp;
- (AAA) Pecan;
- (BBB) *Penicillium notatum*;
- (CCC) Perennial rye;
- (DDD) Poison oak and poison ivy;
- (EEE) Pollens;
- (FFF) Poplar mix;
- (GGG) Prescription;
- (HHH) Ragweed mix;
- (III) Red top grass;
- (JJJ) Respiratory bacterial;
- (KKK) Rough pigweed;
- (LLL) Russian thistle;
- (MMM) Sagebrush common;
- (NNN) Scale mix;
- (OOO) Short ragweed;
- (PPP) Simplified allergy screening set;
- (QQQ) Skin bacterial;
- (RRR) Southern grass;
- (SSS) Staphylococcal;
- (TTT) Stinging insect mix;

- (UUU) Stinging insects;
- (VVV) Sweet vernal;
- (WWW) Sycamore;
- (XXX) Tall ragweed;
- (YYY) Timothy;
- (ZZZ) Tree mix;
- (AAAA) Trees (early spring);
- (BBBB) Walnut;
- (CCCC) Wasp;
- (DDDD) West ragweed;
- (EEEE) West weed mix;
- (FFFF) Yellow jacket;
- (60) Antihemophilic factor, Human;
- (60.3) Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl;
- (60.5) Anti-human globulin;
- (61) Antirabies serum;
- (62) Antivenin;
- (62.03) Apalutamide;
- (62.05) Apixaban;
- (62.1) Apomorphine;
- (62.3) Apraclonidine;
- (62.38) Apremilast;
- (62.4) Aprepitant;
- (62.45) Aprocitentan;
- (62.5) Aprotinin;
- (62.7) Ardeparin;
- (62.75) Arformoterol tartrate;
- (62.8) Argatroban;
- (63) Arginine, L-;
- (63.3) Arimoclomol;

- (63.5) Aripiprazole;
- (64) Arsenic — Preparation for human use;
- (64.1) Arsenic trioxide;
- (65) Artegraft;
- (65.5) Artemether;
- (65.7) Artesunate;
- (65.8) Asciminib;
- (66) Ascorbate sodium — Injection;
- (66.5) Asenapine;
- (66.7) Asfotase;
- (67) Asparaginase;
- (67.3) Asparaginase erwinia chrysanthemi (recombinant)-rywn;
- (67.6) Astemizole;
- (67.67) Astenajavol;
- (67.72) Atazanavir;
- (68.1) Atenolol;
- (68.13) Atezolizumab;
- (68.133) Atidarsagene autotemcel;
- (68.135) Atogepant;
- (68.14) Atoltivimab;
- (68.15) Atomoxetine;
- (68.2) Atorvastatin;
- (68.3) Atovaquone;
- (68.4) Atracurium besylate;
- (68.5) Atropine — See exceptions;
- (68.6) Auranofin;
- (69) Aurothioglucose;
- (69.02) Avacincaptad pegol;
- (69.03) Avacopan;
- (69.05) Avalglucosidase alfa-ngpt;
- (69.07) Avanafil;

- (69.10) Avatrombopag;
- (69.105) Avapritinib;
- (69.11) Avelumab;
- (69.2) Avibactam;
- (69.23) Axatilimab-csfr;
- (69.25) Axicabtagene ciloleucel;
- (69.3) Axitinib;
- (69.5) Azacitidine;
- (70) Azapetine;
- (71) Azatadine maleate;
- (72) Azathioprine;
- (72.3) Azelaic acid;
- (72.4) Azelastine — See exceptions;
- (72.43) Azficel-T;
- (72.45) Azilsartan;
- (72.5) Azithromycin;
- (72.7) Azlocillin;
- (73) Azo-sulfisoxazole;
- (73.5) Aztreonam;
- (74) Azuresin;
- (75) Bacitracin — See exceptions;
- (76) Baclofen;
- (76.3) Baloxavir marboxil;
- (76.5) Balsalazide;
- (76.8) Baricitinib;
- (77) Barium — See exceptions;
- (77.3) Bazedoxifene;
- (77.5) Beclomethasone;
- (78) Bedaquiline;
- (78.2) Belantamab mafodotin-blmf;
- (78.3) Belatacept;

- (78.5) Belimumab;
- (78.7) Belinostat;
- (79) Belladonna;
- (80) Belladonna alkaloids;
- (81) Belladonna extracts;
- (81.2) Belumosudil;
- (81.4) Belzutifan;
- (81.5) Bempedoic acid;
- (82) Benactyzine;
- (82.5) Benazepril;
- (82.7) Bendamustine;
- (83) Bendroflumethiazide;
- (83.1) Benoxaprofen;
- (83.11) Benralizumab;
- (83.2) Bentiromide;
- (83.5) Bentoquatam — See exceptions;
- (84) Benzestrol;
- (84.1) Benznidazole;
- (85) Benzonatate;
- (86) Benzoylpas;
- (87) Benzquinamide;
- (88) Benzthiazide;
- (89) Benztropine;
- (90) Benzylpenicilloyl - polylysine;
- (91) Bephenium hydroxynaphthoate;
- (91.3) Bepotastine;
- (91.5) Bepridil;
- (91.7) Beractant;
- (91.72) Berdazimer;
- (91.73) Beremagene geperpavec-svdt;
- (91.75) Berotralstat;

- (91.8) Besifloxacin;
- (92) Beta-carotene — See exceptions;
- (93) Betadine vaginal gel;
- (94) Betahistine;
- (94.5) Betaine, anhydrous;
- (95) Betamethasone;
- (95.1) Betaxolol;
- (96) Betazole;
- (97) Bethanechol;
- (97.1) Bethanidine sulfate;
- (97.105) Betibeglogene autotemcel;
- (97.11) Betrixaban;
- (97.2) Bevacizumab;
- (97.25) Bexagliflozin;
- (97.3) Bexarotene;
- (97.4) Bezlotoxumab;
- (97.5) Bicalutamide;
- (97.7) Bictegravir sodium;
- (98) Bile extract;
- (98.2) Bimatoprost;
- (98.4) Bimekizumab;
- (98.6) Binimetinib;
- (99) Biperiden;
- (99.5) Birch triterpenes;
- (100) Bisacodyl tannex;
- (101) Bishydroxycoumarin;
- (101.5) Biskalcitrate;
- (102) Bismuth sodium tartrate — See exceptions;
- (102.05) Bisoprolol;
- (102.1) Bitolterol mesylate;
- (102.5) Bivalirudin;

- (103) Blastomycine;
- (104) Bleomycin;
- (104.3) Blinatumomab;
- (104.5) Boceprevir;
- (105) Boroglycerin glycerite;
- (105.3) Bortezomib;
- (105.5) Bosentan;
- (105.6) Bosutinib;
- (105.7) Botulinum toxin (B);
- (106) Botulism antitoxin;
- (106.3) Bremelanotide;
- (106.5) Brentuxima vedotin;
- (107) Bretylium;
- (107.1) Reserved;
- (107.2) Brexpaprazole;
- (107.3) Briazolamide;
- (107.4) Brigatinib;
- (107.45) Brilliant blue G ophthalmic solution;
- (107.5) Brimonidine;
- (107.6) Brodalumab;
- (107.7) Brolucizumab-dblb;
- (108) Bromelains — See exceptions;
- (108.5) Bromfenac;
- (109) Bromisovalum;
- (110) Bromocriptine;
- (111) Bromodiphenhydramine;
- (112) Brompheniramine — See exceptions;
- (113) Brucella antigen;
- (114) Brucella protein nucleate;
- (115) Buclizine;
- (115.3) Budesonide — See exceptions;

- (115.5) Bumetanide;
- (116) Bupivacaine;
- (116.1) Bupropion;
- (116.3) Burosumab-twza;
- (116.5) Buspirone;
- (117) Busulfan;
- (118) Butacaine;
- (119) Butaperazine;
- (119.05) Butenafine — See exceptions;
- (119.1) Butoconazole — See exceptions;
- (120) Reserved;
- (121) Butyl nitrite;
- (122) Butyrophenone;
- (122.3) Cabazitaxel;
- (122.5) Cabergoline;
- (122.6) Cabotegravir;
- (122.7) Cabozantinib;
- (123) Cadmium sulfide — See exceptions;
- (124) Caffeine sodium benzoate;
- (124.1) Calaspargase pegol-mknl;
- (124.3) Calcifediol;
- (124.7) Calcipotriene;
- (125) Calcitonin, Salmon;
- (126) Calcitriol;
- (127) Calcium disodium edetate — See exceptions;
- (128) Calcium gluconogalactogluconate;
- (129) Calcium levulinate;
- (129.5) Calfactant;
- (130) Calusterone;
- (130.1) Canagliflozin;
- (130.3) Canakinumab;

(130.5) Candesartan;
(131) Candicidin;
(131.5) Cangrelor;
(132) Cantharidin;
(132.5) Capecitabine;
(132.6) Capivasertib;
(132.7) Caplacizumab-yhdp;
(132.9) Capmatinib;
(133) Capreomycin;
(133.05) Capsaicin — See exceptions;
(133.1) Captopril;
(134) Capyodiame;
(135) Caramiphen;
(136) Carbachol;
(137) Carbamazepine;
(138) Carbazochrome;
(139) Carbenicillin;
(140) Carbetapentane;
(141) Carbidopa;
(142) Carbinoxamine;
(142.5) Carboplatin;
(142.7) Carfilzomib;
(143) Carglumic Acid;
(143.5) Cariprazine;
(144) Carmustine;
(144.1) Carnitine;
(145) Carphenazine;
(145.6) Carteolol;
(145.8) Carvedilol;
(146) Casein hydrolysate;
(146.3) Casimersen;

- (146.6) Caspofungin;
- (147) Catarrhalis combined vaccine;
- (148) Catarrhalis vaccine mixed;
- (148.5) Cedazuridine;
- (149) Cefaclor;
- (150) Cefadroxil;
- (151) Cefamandole;
- (151.3) Cefazolin;
- (151.4) Cefdinir;
- (151.45) Cefditoren;
- (151.5) Cefepime;
- (151.55) Cefiderocol;
- (151.6) Cefixime;
- (151.7) Cefmetazole;
- (151.8) Cefonicid;
- (152) Cefoperazone;
- (152.1) Ceforanide;
- (152.2) Cefotaxime;
- (152.3) Cefotetan;
- (152.7) Cefotiam;
- (152.9) Cefoxitin;
- (153.1) Cefpiramide;
- (153.2) Cefpodoxime;
- (153.3) Cefprozil;
- (153.35) Ceftaroline;
- (153.4) Ceftazidime;
- (153.5) Ceftibuten;
- (153.6) Ceftizoxime;
- (153.65) Ceftobiprole medocaril sodium;
- (153.7) Ceftolozane;
- (153.8) Ceftriaxone;

- (153.9) Cefuroxime;
- (153.95) Celecoxib;
- (154) Cellulose, Oxadized, Regenerated — See exceptions;
- (154.3) Cemiplimab-rwlc;
- (154.4) Cenegermin-bkbj;
- (154.45) Reserved;
- (154.5) Centruroides [Scorpion] Immune;
- (155) Cephalixin;
- (156) Cephaloglycin;
- (157) Cephaloridine;
- (158) Cephalothin;
- (159) Cephapirin;
- (159.3) Cephradine;
- (159.6) Ceretec;
- (159.7) Ceritinib;
- (159.8) Cerivastatin;
- (159.9) Cerliponase alfa;
- (160) Certolizumab;
- (160.1) Ceruletide;
- (160.15) Cetirizine — See exceptions;
- (160.16) Cetrorelix;
- (160.165) Cetuximab;
- (160.17) Cevimeline;
- (160.20) Chenodiol;
- (160.5) Chikungunya vaccine, Live;
- (161) Chlophedianol;
- (162) Chlorambucil;
- (163) Chloramphenicol;
- (164) Chloranil — See exceptions;
- (165) Chlordantoin;

(166) Chlordiazepoxide in combination with clidinium bromide or water soluble esterified estrogens;

(166.5) Chlorhexidine — See exceptions;

(167) Chlormadinone;

(168) Chlormerodrin;

(169) Chlormezanone;

(170) Chloroacetic acid — See exceptions;

(171) Chlorobutanol — See exceptions;

(172) Chloroform — See exceptions;

(173) Chloroguanide;

(174) Chloroprocaine;

(175) Chloroquine;

(176) Chlorothiazide;

(177) Chlorotrianisene;

(178) Chloroxine;

(179) Chlorphenesin;

(180) Chlorpheniramine — See exceptions;

(181) Chlorphenoxamine;

(182) Chlorpromazine;

(183) Chlorpropamide;

(184) Chlorprothixene;

(185) Chlorquinaldol;

(186) Chlortetracycline;

(187) Chlorthalidone;

(188) Chlorzoxazone;

(189) Cholera vaccine;

(190) Cholestyramine resin;

(190.3) Cholic Acid;

(190.5) Choline C 11;

(191) Chondroitin;

(191.5) Chymopapain;

- (192) Chymotrypsin;
- (192.02) Ciclesonide;
- (192.03) Ciclopirox;
- (192.05) Cidofovir;
- (192.1) Cilastatin;
- (192.4) Cilexetil;
- (192.7) Cilostazol;
- (192.8) Ciltacabtagene autoleucel;
- (193) Cimetidine — See exceptions;
- (193.5) Cinacalcet;
- (194) Cinoxacin;
- (194.2) Cipaglucoasidase alfa-atga;
- (194.5) Ciprofloxacina;
- (194.7) Cisapride;
- (194.8) Cisatracurium;
- (195) Cisplatina;
- (195.2) Citalopram;
- (195.3) Cladribina;
- (195.5) Clarithromycin;
- (195.6) Clascoterone;
- (195.7) Clavulanate;
- (196) Clemastina — See exceptions;
- (196.5) Clevidipina;
- (197) Clidinium bromide;
- (198) Clindamycin;
- (198.1) Clobetasol propionate;
- (199) Clacortolona pivalate;
- (200) Clofibrate;
- (201) Clomiphene;
- (201.5) Clomipramina;
- (202) Clonidine;

- (203) Clopidogrel;
- (204) Clostridiopeptidase;
- (205) Clotrimazole — See exceptions;
- (206) Cloxacillin;
- (206.5) Clozapine;
- (206.6) Coagulation Factor IX (recombinant);
- (206.7) Coagulation Factor X, Human;
- (207) Coal tar solution topical;
- (207.5) Cobicistat;
- (207.7) Cobimetinib;
- (208) Cobra venom;
- (208.5) *Coccidioides immitis*;
- (209) Colchicine — See exceptions;
- (209.5) Colesevelam;
- (210) Colestipol;
- (211) Colistimethate;
- (212) Colistin;
- (213) Collagenase;
- (213.1) Collagenase clostridium histolyticum;
- (213.2) Concizumab-mtci;
- (213.3) Conivaptan;
- (213.4) Copanlisib;
- (213.45) Copper dotatate Cu-64;
- (213.5) Corticorelin;
- (214) Corticotropin;
- (215) Corticotropin, Respository;
- (216) Cortisone;
- (216.5) Cosibelimab-ipdl;
- (217) Cosyntropin;
- (217.2) COVID-19 Vaccine, mRNA;
- (217.3) Crinecerfont;

- (217.4) Crisaborole;
- (217.5) Crixivan;
- (217.7) Crizanlizumab-tmca;
- (217.8) Crizotinib;
- (217.9) Crofelemer;
- (218) Cromolyn — See exceptions;
- (219) Crotaline antivenin, Polyvalent;
- (220) Crotamiton;
- (220.5) Crovalimab-akkz;
- (221) Cryptenamine;
- (221.5) Cupric chloride — injectable;
- (222) Cyanide antidote;
- (223) Cyclacillin;
- (224) Cyclandelate;
- (225) Reserved;
- (226) Cyclobenzaprine;
- (227) Cyclomethycaine;
- (228) Cyclopentamine;
- (229) Cyclopentolate;
- (230) Cyclophosphamide;
- (231) Cycloserine;
- (231.5) Cyclosporine;
- (232) Cyclothiazide;
- (233) Cycrimine;
- (234) Cyproheptadine;
- (234.5) Cysteamine;
- (235) Cytarabine;
- (235.5) Dabigatran;
- (235.7) Dabrafenib;
- (236) Dacarbazine;
- (236.5) Daclatasvir;

- (236.6) Daclizumab;
- (236.8) Dacomitinib;
- (237) Dactinomycin;
- (237.05) Dalbavancin;
- (237.1) Dalfampridine;
- (237.2) Dalfopristin;
- (237.5) Dalteparin;
- (237.7) Danaparoid;
- (238) Danazol;
- (238.5) Danicopan;
- (239) Dantrolene;
- (239.4) Dapagliflozin;
- (239.5) Dapiprazole;
- (239.7) Daprodustat;
- (240) Dapsone — See exceptions;
- (240.3) Daptomycin;
- (240.4) Daratumumab;
- (240.5) Darbepoetin alfa;
- (240.6) Darifenacin;
- (240.65) Darolutamide;
- (240.7) Darunavir;
- (240.8) Dasabuvir;
- (240.9) Dasatinib;
- (240.95) Dasiglucagon;
- (241) Daunorubicin;
- (241.5) DaxibotulinumtoxinA-lanm;
- (242) Deanol;
- (243) Decamethonium;
- (243.3) Decitabine;
- (243.5) Deferasirox;
- (243.7) Deferiprone;

- (244) Deferoxamine;
- (244.2) Defibrotide;
- (244.3) Deflazacort;
- (244.4) Degarelix;
- (244.41) Delafloxacin;
- (244.45) Delandistrogene moxeparvovec-rokl;
- (244.5) Delavirdine;
- (245) Demecarium;
- (246) Demeclocycline;
- (247) Demethylchlortetracycline;
- (247.4) Dengue tetravalent vaccine, Live;
- (247.7) Denosumab;
- (247.8) Deoxycholic Acid;
- (248) Deoxyribonuclease, Pancreatic;
- (249) Deserpidine;
- (249.5) Desflurane;
- (250) Desipramine;
- (250.5) Desirudin;
- (251) Deslanoside;
- (251.5) Desloratadine;
- (252) Desmopressin;
- (252.5) Desogestrel;
- (253) Desonide;
- (254) Desoximetasone;
- (255) Desoxycorticosterone;
- (256) Desoxyribonuclease;
- (256.5) Desvenlafaxine;
- (256.55) Deucravacitinib;
- (256.58) Deuruxolitinib;
- (256.6) Deutetrabenazine;
- (256.8) Deutivacaftor;

- (257) Dexamethasone;
- (258) Dexbrompheniramine — See exceptions;
- (259) Dexchlorpheniramine;
- (259.5) Dexlansoprazole;
- (260) Dexpanthenol;
- (260.5) Dexrazoxane;
- (261) Dextran;
- (262) Reserved;
- (263) Dextriferron;
- (264) Dextroisoephedrine;
- (265) Dextrothyroxine;
- (265.5) Dezocine;
- (266) Diatrizoate;
- (267) Diazoxide;
- (268) Dibucaine;
- (269) Dichloralphenazone;
- (270) Dichlorphenamide;
- (270.5) Diclofenac — See exceptions;
- (271) Dicloxacillin;
- (272) Dicyclomine;
- (272.5) Didanosine;
- (273) Dienestrol;
- (273.5) Dienogest;
- (274) Diethylcarbamazine;
- (275) Diethylstilbestrol;
- (276) Difelikefalin;
- (277) Diflorasone diacetate;
- (277.5) Diflunisal;
- (277.57) Difluprednate;
- (278) Digitalis;
- (279) Digitoxin;

- (280) Digoxin;
- (281) Dihydroergocornine;
- (282) Dihydroergocristine;
- (283) Dihydroergocryptine;
- (284) Dihydroergotamine;
- (285) Dihydrostreptomycin;
- (286) Dihydrotachysterol;
- (287) Diiodohydroxyquin;
- (287.5) Diltiazem;
- (288) Dimenhydrinate — Injection or suppositories;
- (289) Dimercaprol;
- (290) Dimethindene;
- (291) Dimethisterone;
- (291.5) Dimethyl fumarate;
- (292) Dimethyl sulfoxide — See exceptions;
- (293) Dimethyl tubocurarine;
- (293.5) Dimyristoyl;
- (294) Dinoprost;
- (295) Dinoprostone;
- (295.5) Dinutuximab;
- (296) Dioxyline;
- (297) Diphemanil;
- (298) Diphenadione;
- (299) Diphenhydramine — See exceptions;
- (300) Diphenidol;
- (301) Diphenylhydantoin;
- (302) Diphenylpyraline;
- (303) Diphtheria antitoxin;
- (304) Diphtheria and tetanus toxoids;
- (305) Diphtheria and tetanus toxoids and pertussis vaccine;
- (306) Diphtheria and tetanus toxoids, Absorbed;

- (307) Diphtheria and tetanus toxoids, Pertussis;
- (308) Diphtheria toxoid;
- (309) Dipivefrin;
- (310) Dipyridamole;
- (311) Dipyrone;
- (311.3) Dirithromycin;
- (311.5) Disibind;
- (312) Disodium edetate — See exceptions;
- (313) Disopyramide;
- (314) Disulfiram;
- (314.5) Divalproex;
- (315) Dobutamine;
- (315.5) Docetaxel;
- (315.7) Docosanol — See exceptions;
- (316) Doderlein bacilli;
- (316.2) Dofetilide;
- (316.3) Dolasetron;
- (316.4) Dolutegravir;
- (316.45) Donanemab-azbt;
- (316.5) Donepezil;
- (316.7) Donislecel-jujn;
- (317) Dopamine;
- (317.1) Doravirine;
- (317.2) Doripenem;
- (317.3) Dornase alpha;
- (317.4) Dorzolamide;
- (317.45) Dostarlimab-gxly;
- (317.5) Doxacurium;
- (318) Doxapram;
- (318.5) Doxazosin mesylate;
- (319) Doxepin;

- (319.5) Doxercalciferol;
- (320) Doxorubicin;
- (321) Doxycycline;
- (322) Reserved;
- (323) Doxylamine;
- (324) Dromostanolone;
- (324.5) Dronedarone;
- (325) Droperidol;
- (325.3) Drospirenone;
- (325.4) Drotrecogin alfa;
- (325.43) Droxidopa;
- (325.44) Dulaglutide;
- (325.45) Duloxetine;
- (325.46) Dupilumab;
- (325.465) Durlobactam;
- (325.47) Durvalumab;
- (325.5) Dutasteride;
- (325.8) Duvelisib;
- (326) Dyclonine;
- (327) Dydrogesterone;
- (328) Dyphylline;
- (328.3) Ebola Zaire vaccine, Live;
- (328.5) Ecallantide;
- (329) Echothiophate;
- (329.5) Econazole;
- (330) Ectylurea;
- (330.3) Eculizumab;
- (330.4) Edaravone;
- (330.5) Edetate — See exceptions;
- (330.7) Edoxaban;
- (331) Edrophonium;

- (331.03) Efavirenz;
- (331.033) Efbemalenograstim alfa-vuxw;
- (331.035) Efgartigimod alfa-fcab;
- (331.04) Efinaconazole;
- (331.045) Eflapegrastim;
- (331.05) Eflornithine;
- (331.0502) Elacestrant;
- (331.0504) Eladocagene exuparvovec-tneq;
- (331.0506) Elafibranor;
- (331.051) Elagolix sodium;
- (331.0515) Elaparvovec-dzkt;
- (331.052) Elapegademase-lvlr;
- (331.053) Elbasvir;
- (331.0535) Elecsys HIV Duo;
- (331.0536) Elecsys HTLV-I/II;
- (331.054) Elexacaftor;
- (331.055) Eliglustat;
- (331.056) Elivaldogene autotemcel;
- (331.058) Elosulfase;
- (331.059) Elotuzumab;
- (331.0595) Elranatamab-bcmm;
- (331.06) Eltrombopag;
- (331.065) Elvitegravir;
- (331.068) Emapalumab-lzsg;
- (331.07) Emedastine;
- (331.0701) Emicizumab;
- (331.071) Empagliflozin;
- (331.072) Emtricitabine;
- (331.1) Enalapril;
- (331.6) Enalaprilat;
- (331.7) Enasidenib;

- (331.9) Encorafenib;
- (332) Enflurane;
- (332.1) Enfortumab vedotin-ejfv;
- (332.2) Enfuvirtide;
- (332.3) Enmetazobactam;
- (332.5) Enoxacin;
- (332.7) Enoxaparin;
- (332.73) Ensartinib;
- (332.75) Ensifentrine;
- (332.8) Entacapone;
- (332.85) Entecavir;
- (332.86) Entrectinib;
- (332.87) Enzalutamide;
- (332.875) Epcoritamab-bysp;

(332.88) Epidiolex: A drug product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the United States Food and Drug Administration (FDA) that contains cannabidiol (CBD) derived from cannabis and contains no more than 0.1 percent (w/w) residual tetrahydrocannabinols;

- (332.9) Epinastine;
- (333) Epinephrine — See exceptions;
- (334) Epinephryl borate;
- (334.3) Epirubicin;
- (334.4) Eplerenone;
- (334.42) Eplontersen;
- (334.45) Epoetin alfa;
- (334.5) Epoprostenol;
- (334.7) Eprosartan;
- (334.8) Eptifibatide;
- (334.85) Eptinezumab-jjmr;
- (334.9) Eravacycline;

- (334.91) Erdafitinib;
- (334.92) Erenumab-aooe;
- (335) Ergocalciferol — See exceptions;
- (335.5) Ergoloid mesylates;
- (336) Ergonovine;
- (337) Ergotamine;
- (338) Ergosine;
- (339) Ergocristine;
- (340) Ergocryptine;
- (341) Ergocornine;
- (342) Ergotaminine;
- (343) Ergosinine;
- (344) Ergocristinine;
- (345) Ergocryptinine;
- (346) Ergocorninine;
- (346.05) Eribulin;
- (346.1) Erlotinib;
- (346.5) Ertapenem;
- (346.7) Ertugliflozin;
- (347) Erythrityl tetranitrate;
- (348) Erythromycin;
- (348.722) Escitalopram;
- (349) Eserine;
- (349.3) Eslicarbazepine;
- (349.4) Esmolol;
- (349.7) Esomeprazole — See exceptions;
- (350) Esterified estrogens;
- (350.5) Estetrol;
- (351) Estradiol;
- (352) Estriol;
- (353) Estrogens;

- (354) Estrogenic substances;
- (355) Estrone;
- (355.5) Estropipate;
- (355.55) Etanercept;
- (355.6) Etanercept-szzs;
- (355.7) Etelcalcetide;
- (355.8) Eteplirsen;
- (356) Ethacrynate;
- (357) Ethacrynic acid;
- (358) Ethambutol;
- (359) Ethamivan;
- (359.5) Ethanolamine oleate;
- (360) Ethaverine;
- (361) Ether — See exceptions;
- (362) Ethinyl estradiol;
- (363) Ethiodized oil;
- (364) Ethionamide;
- (365) Ethisterone;
- (366) Ethoheptazine;
- (367) Ethopropazine;
- (368) Ethosuximide;
- (369) Ethotoin;
- (370) Ethoxazene — See exceptions;
- (371) Ethoxyzolamide;
- (372) Ethyl biscoumacetate;
- (373) Ethyl chloride — See exceptions;
- (374) Ethyl nitrite spirit;
- (375) Reserved;
- (376) Ethylnorepinephrine;
- (377) Ethynodiol diacetate;
- (378) Etidocaine;

- (379) Etidronate;
- (379.05) Etodolac;
- (379.07) Etomidate;
- (379.09) Etonogestrel;
- (379.1) Etoposide;
- (379.4) Etrasimod;
- (379.5) Etravirine;
- (380) Eucatropine;
- (380.3) Everolimus;
- (380.35) Evinacumab-dgnb;
- (380.4) Evolocumab;
- (380.45) Exagamglogene autotemcel;
- (380.5) Exemestane;
- (380.6) Exenatide;
- (380.7) Ezetimibe;
- (381) Factor IX complex, Human;
- (381.1) Famciclovir;
- (381.2) Famotidine — See exceptions;
- (381.23) Faricimab-svoa;
- (381.24) Fecal microbiota spores, live-brpk;
- (381.25) Fedratinib;
- (381.3) Felbamate;
- (381.5) Felodipine;
- (381.55) Fenfibrate;
- (381.57) Fenfluramine;
- (381.6) Fenofenadine;
- (381.7) Fenofibrate;
- (381.75) Fenofibric acid;
- (381.8) Fenoldopam;
- (382) Fenoprofen;
- (382.25) Febuxostat;

- (383) Ferric cacodylate;
- (383.15) Ferric hexacyanoferrate;
- (383.2) Ferric maltol;
- (383.3) Ferumoxides;
- (383.4) Ferumoxsil;
- (383.43) Ferumoxytol;
- (383.45) Fesoterodine;
- (383.47) Fexinidazole;
- (383.5) Fexofenadine — See exceptions;
- (383.7) Fezolinetant;
- (384) Fibrinogen;
- (385) Fibrinogen/antihemophilic factor, Human;
- (386) Fibrinolysin, Human;
- (386.05) Fidaxomicin;
- (386.1) Filgrastim-SNDZ;
- (386.5) Filgrastim;
- (386.6) Finafloxacin;
- (386.63) Finasteride;
- (386.65) Finerenone;
- (386.7) Fingolimod;
- (386.9) Fish oil triglycerides;
- (387) Flavoxate;
- (387.1) Flecainide acetate;
- (387.7) Flibanserin;
- (388) Florantyrone;
- (388.3) Florbetapir F 18;
- (388.4) Flortaucipir F 18;
- (388.5) Flosequinan;
- (388.7) Flotufolastat F 18;
- (389) Floxuridine;
- (389.5) Fluconazole;

- (390) Flucytosine;
- (390.5) Fludarabine;
- (390.7) Fludeoxyglucose;
- (391) Fludrocortisone;
- (391.5) Flumazenil;
- (392) Flumethasone;
- (392.1) Flunisolide;
- (393) Fluocinonide;
- (394) Fluocinolone;
- (395) Fluorescein;
- (396) Fluoride — See exceptions;
- (396.3) Fluorodopa F 18;
- (396.4) Fluoroestradiol F 18;
- (396.5) Fluorometholone;
- (397) Fluorophosphates;
- (398) Fluorouracil;
- (399) Fluoxetine;
- (399.5) Fluoxymesterone;
- (400) Fluphenazine;
- (401) Fluprednisolone;
- (402) Flurandrenolide;
- (402.2) Flurbiprofen;
- (402.3) Flurpiridaz F 18;
- (402.5) Flutamide;
- (402.6) Flutemetamol F18;
- (402.7) Fluticasone — See exceptions;
- (402.8) Fluvastatin;
- (402.9) Fluvoxamine;
- (403) Folate sodium;
- (404) Folic acid — See exceptions;
- (404.3) Follitropin;

- (404.5) Fomivirsen;
- (404.7) Fondaparinux;
- (405) Foreign protein;
- (406) Formaldehyde — See exceptions;
- (406.2) Formoterol;
- (406.3) Fosamprenavir;
- (406.35) Fosaprepitant;
- (406.4) Foscarnet;
- (406.45) Fosdenopterin;
- (406.5) Fosfomycin;
- (406.7) Fosinopril;
- (406.9) Fosphenytoin;
- (406.93) Fostamatinib;
- (406.935) Fostemsavir;
- (406.94) Fremanezumab-vfrm;
- (406.95) Frovatriptan;
- (406.97) Fruquintinib;
- (407) Furazolidone;
- (408) Furosemide;
- (408.05) Futibatinib;
- (408.1) Ga-68-DOTATOC;
- (408.2) Gabapentin;
- (408.25) Gadobenate;
- (408.27) Gadobutrol;
- (408.3) Gadodiamide;
- (408.35) Gadofosveset;
- (408.4) Gadopentetate dimeglumine;
- (408.45) Gadopiclenol;
- (408.5) Gadoterate meglumine;
- (408.6) Gadoteridol;
- (408.8) Gadoversetamide;

- (408.85) Gadoxetate;
- (408.9) Galantamine;
- (408.95) Galcanezumab-gnlm;
- (409) Gallamine triethiodide;
- (409.1) Gallium 68 PSMA-11;
- (409.3) Gallium citrate;
- (409.5) Gallium nitrate;
- (409.8) Galsulfase;
- (410) Gamma benzene hexachloride;
- (411) Gamma globulin;
- (411.5) Ganciclovir;
- (411.7) Ganirelix;
- (412) Gas gangrene polyvalent antitoxin;
- (412.03) Gatifloxacin;
- (412.04) Gefitinib;
- (412.05) Gemcitabine;
- (412.1) Gemfibrozil;
- (412.2) Gemifloxacin;
- (412.3) Gemtuzumab ozogamicin;
- (412.5) Genotropin;
- (413) Gentamicin;
- (414) Gentian violet vaginal suppositories;
- (414.3) Gepirone;
- (414.5) Gilteritinib;
- (415) Gitalin;
- (415.005) Givinostat;
- (415.01) Givosiran;
- (415.02) Glasdegib;
- (415.03) Glatiramer;
- (415.04) Glecaprevir;
- (415.05) Glimepiride;

- (415.1) Glipizide;
- (415.6) Glofitamab-gxbm;
- (416) Glucagon;
- (416.5) Glucarpidase;
- (417) Gluceptate;
- (418) Gluconate magnesium;
- (419) Gluconate potassium — See exceptions;
- (420) Glutamate arginine;
- (420.1) Glyburide;
- (420.2) Glycerol phenylbutyrate;
- (420.5) Glycine — See exceptions;
- (421) Glycobiarsol;
- (422) Glycopyrrolate;
- (423) Gold sodium thiomalate;
- (424) Gold thiosulfate — See exceptions;
- (424.4) Golimumab;
- (424.6) Golodirsen;
- (425) Gomenol solution;
- (425.5) Gonadorelin acetate;
- (426) Gonadotropin, Chorionic;
- (427) Gonadotropin, Chorionic, Anti-human serum;
- (428) Gonadotropin, Serum;
- (428.5) Goserelin;
- (429) Gramicidin;
- (430) Gramineae pollens;
- (430.3) Gramosetron;
- (430.5) Granisetron;
- (430.7) Grazoprevir;
- (431) Griseofulvin;
- (431.5) Guanabenz;
- (432) Guanethidine;

- (432.4) Guanadrel;
- (432.7) Guanfacine;
- (432.9) Guanidine;
- (432.91) Guselkumab;
- (433) Halcinonide;
- (433.5) Halobetasol propionate;
- (433.7) Halofantrine;
- (434) Haloperidol;
- (435) Haloproglin;
- (436) Halothane;
- (437) Hartman's solution;
- (438) Heparin;
- (438.3) Hepatitis C virus (E. coli, recombinant) NS3 helicase antigens and synthetic core peptide;
- (438.5) Hepatitis vaccine;
- (439) Hetacillin;
- (440) Hexachlorophene — See exceptions;
- (441) Hexafluoremium;
- (442) Hexocyclium;
- (443) Hexylcaine;
- (444) Histamine;
- (445) Histoplasmin;
- (445.5) Histrelin acetate;
- (446) Homatropine;
- (446.2) Human papillomavirus 9-valent vaccine, Recombinant;
- (446.4) Human secretin;
- (446.6) Hyaluronan;
- (446.7) Hyaluronic acid;
- (447) Hyaluronidase;
- (448) Hydralazine;
- (449) Hydrocalciferol;

- (450) Hydrochlorothiazide;
- (451) Hydrocortamate;
- (452) Hydrocortisone — See exceptions;
- (453) Hydroflumethiazide;
- (454) Hydroquinone;
- (455) Hydroxocobalamin — See exceptions;
- (456) Hydroxyamphetamine;
- (457) Hydroxychloroquine;
- (458) Hydroxyprogesterone;
- (459) Hydroxyurea;
- (460) Hydroxyzine;
- (461) Hyoscyamine;
- (462) Hyoscyamus alkaloids;
- (462.5) Hyperpolarized Xe-129;
- (463) Hypophamine;
- (463.01) Ibalizumab-uiyk;
- (463.03) Ibandronate;
- (463.3) Ibrexafungerp;
- (463.5) Ibrutinib;
- (464) Ibuprofen — See exceptions;
- (464.05) Ibutilide;
- (464.07) Icatibant;
- (464.1) Idarubicin;
- (464.15) Idarucizumab;
- (464.17) Idecabtagene vicleucel;
- (464.2) Idelalisib;
- (464.3) Idoxuridine;
- (464.5) Idursulfase;
- (464.6) Ifosfamide;
- (464.67) Iloperidone;
- (464.7) Iloprost;

- (464.8) Imatinib;
- (464.9) Imetelstat;
- (465) Imiglucerase;
- (465.1) Imipenem/cilastatin;
- (466) Imipramine;
- (466.5) Imiquimod;
- (466.8) Immune globulin, Human;
- (467) Immune hepatitis B globulin, Human;
- (468) Immune poliomyelitis globulin, Human;
- (469) Immune serum globulin, Human;
- (469.02) Inavolisib;
- (469.03) Inclisiran;
- (469.05) IncobotulinumtoxinA;
- (469.07) Indacaterol;
- (469.1) Indapamide;
- (469.5) Indecainide;
- (470) Indigotindisulfonate;
- (470.05) Indinavir;
- (470.1) Indium IN-III oxyquinolone;
- (470.3) Indium IN-III pentetreotide;
- (471) Indocyanine green;
- (472) Indomethacin;
- (472.3) Inebilizumab-cdon;
- (472.4) Infigratinib;
- (472.5) Infliximab;
- (472.51) Infliximab-dyyb;
- (473) Influenza virus vaccines;
- (473.5) Ingenol mebutate;
- (474) Injections, All substances for human use — See exceptions;
- (474.01) Inotersen;
- (474.1) Inotuzumab ozogamicin;

- (474.2) Insulin aspart;
- (474.3) Insulin degludec;
- (474.4) Insulin glargine;
- (474.45) Insulin glulisine;
- (474.5) Interferon;
- (475) Intrinsic factor concentrate manufactured for human use;
- (475.3) Inulin;
- (475.5) Iobenguane;
- (476) Iocetamic acid;
- (477) Iodamide;
- (478) Iodinated I-125 serum albumin;
- (479) Iodinated I-131 serum albumin;
- (480) Iodinated glycerol-theophylline;
- (481) Iodine solution, Strong oral;
- (482) Iodipamide;
- (482.5) Iodixanol;
- (483) Iodized oil;
- (484) Iodobenzoic acid — See exceptions;
- (485) Iodobrassid;
- (485.1) Iodohippurate sodium;
- (486) Iodopyracet;
- (487) Iodothiouracil;
- (487.05) Iofetamine;
- (487.06) Ioflupane;
- (487.08) Iohexol;
- (487.09) Iomeprol;
- (487.1) Iopamidol;
- (488) Iopanoic acid — See exceptions;
- (489) Iophendylate;
- (489.1) Iopromide;
- (489.2) Iothalamate;

- (489.3) Iothiouracil;
- (489.5) Iotrolan;
- (489.6) Ioversol;
- (490.1) Ioxaglate;
- (490.5) Ioxilan;
- (490.7) Ipilimumab;
- (491) Ipodate;
- (491.5) Ipratropium;
- (491.55) Iptacopan;
- (491.6) Irbesartan;
- (491.7) Irinotecan;
- (492) Iron cacodylate;
- (493) Iron dextran injection;
- (494) Iron peptonized;
- (495) Iron sorbitex;
- (495.3) Isatuximab;
- (495.5) Isavuconazonium;
- (496) Isocarboxazid;
- (497) Isoetharine;
- (498) Isoflurane;
- (499) Isoflurophate;
- (500) Isometheptene;
- (501) Isoniazid;
- (502) Isopropamide;
- (503) Isoproterenol;
- (504) Isosorbide dinitrate;
- (504.05) Isosorbide mononitrate;
- (504.1) Isosulfan blue;
- (505) Isothipendyl;
- (505.5) Isotretinoin;
- (506) Isoxsuprine;

- (506.5) Isradipine;
- (506.6) Istradefylline;
- (506.7) Itraconazole;
- (506.72) Ivabradine;
- (506.75) Ivacaftor;
- (506.8) Ivermectin — See exceptions;
- (506.85) Ivosidenib;
- (506.9) Ixabepilone;
- (506.95) Ixazomib;
- (506.97) Ixekizumab;
- (507) Kanamycin;
- (508) Reserved;
- (509) KetochoLANic acids;
- (509.1) Ketoconazole — See exceptions;
- (509.15) Ketoprofen — See exceptions;
- (509.17) Ketorolac tromethamine;
- (509.18) Ketotifen — See exceptions;
- (509.2) Labetalol;
- (510) Lactated ringers solution;
- (510.5) Lactitol;
- (511) Lactulose;
- (511.3) Lamivudine;
- (511.5) Lamotrigine;
- (511.55) Lanadelumab;
- (512) Lanatoside C;
- (512.1) Landiolol;
- (512.3) Lanreotide;
- (512.5) Lansoprazole — See exceptions;
- (512.6) Lanthanum;
- (512.67) Lapatinib;
- (512.69) Larotrectinib;

- (512.7) Latanoprost;
- (512.8) Latanoprostene bunod;
- (513) Latrodectus mactans;
- (513.03) Lazertinib;
- (513.07) Lebrikizumab-lbkz;
- (513.1) Lecanemab-irmb;
- (513.3) Ledipasvir;
- (513.4) Lefamulin;
- (513.5) Leflunomide;
- (513.6) Lenacapavir;
- (513.7) Lenalidomide;
- (513.72) Leniolisib;
- (513.74) Lenvatinib;
- (513.77) Lesinurad;
- (513.78) Letermovir;
- (513.79) LetibotulinumtoxinA-wlbg;
- (513.8) Letrozole;
- (514) Leucovorin;
- (514.1) Leuprolide;
- (514.3) Levacetylleucine;
- (514.5) Levalbuterol;
- (515) Reserved;
- (515.5) Levamisole;
- (516) Levarterenol;
- (516.05) Levetiracetam;
- (516.07) Levobetaxolol;
- (516.1) Levobunolol;
- (516.3) Levobupivacine;
- (516.5) Levocabastine;
- (516.7) Levocarnitine;
- (516.75) Levocetirizine dihydrochloride — See exceptions;

- (517) Levodopa;
- (517.2) Levofloxacin;
- (517.25) Levoleucovorin;
- (517.3) Levomethadyl;
- (517.35) Levomilnacipran;
- (517.4) Levonordefrin;
- (518) Levopropoxyphene;
- (519) Levothyroxine;
- (520) Lidocaine — See exceptions;
- (520.1) Lifleucel;
- (520.2) Lifitegrast;
- (520.3) Linacotide;
- (520.5) Linagliptin;
- (521) Lincomycin;
- (522) Lindane — See exceptions;
- (522.5) Linezolid;
- (523) Linolenic acid;
- (524) Liothyronine;
- (525) Liotrix;
- (525.2) Liraglutide;
- (525.5) Lisinopril;
- (525.7) Lisocabtagene maraleucel;
- (526) Lithium carbonate — See exceptions;
- (527) Lithium citrate;
- (528) Liver extract;
- (528.1) Lixisenatide;
- (528.3) Lodoxamide;
- (528.4) Lofexidine hydrochloride;
- (528.5) Lomefloxacin;
- (528.7) Lomitapide;
- (529) Lomustine;

- (529.05) Lonafarnib;
- (529.07) Lonapegsomatropin-tcgd;
- (529.08) Loncastuximab tesirine-lpyl;
- (529.1) Loperamide — See exceptions;
- (529.5) Lopinavir;
- (529.7) Loracarbef;
- (529.9) Loratadine — See exceptions;
- (529.94) Lorlatinib;
- (529.95) Losartan;
- (529.97) Loteprednol;
- (529.98) Lotilaner;
- (530) Lovastatin;
- (530.3) Lovotibeglogene autotemcel;
- (530.5) Loxapine;
- (530.7) Lubiprostone;
- (530.8) Lucinactant;
- (531) Lugols solution;
- (531.3) Luliconazole;
- (531.4) Lumacaftor;
- (531.43) Lumasiran;
- (531.45) Lumateperone tosylate;
- (531.5) Lumefantrine;
- (531.7) Lurasidone;
- (531.73) Lurbinectedin;
- (531.75) Luspatercept-aamt;
- (531.8) Lusutrombopag;
- (531.9) Lutetium Lu 177 dotatate;
- (531.95) Lutetium (177Lu) vipivotide tetraxetan;
- (532) Lututrin;
- (533) Lymphogranuloma venereum antigen;
- (534) Lypressin synthetic;

- (534.3) Macimorelin;
- (534.5) Macitentan;
- (535) Mafenide;
- (535.5) Maftivimab;
- (536) Magnesium gluconate — See exceptions;
- (537) Magnesium salicylate;
- (538) Mandelic acid — See exceptions;
- (539) Mannitol — See exceptions;
- (540) Mannitol hexanitrate;
- (540.1) Maprotiline;
- (540.2) Maralixibat;
- (540.3) Maraviroc;
- (540.4) Margetuximab — anti HER2 mAb;
- (540.45) Maribavir;
- (540.47) Marstacimab-hncq;
- (540.5) Masoprocol;
- (540.7) Mavacamten;
- (540.8) Mavorixafor;
- (541) Measles immune globulin, Human;
- (542) Measles virus vaccines;
- (543) Mebendazole for human use;
- (544) Mecamylamine;
- (544.5) Mecasermin;
- (545) Mechlorethamine;
- (546) Meclizine — See exceptions;
- (546.5) Meclocycline;
- (547) Meclofenamate;
- (548) Medroxyprogesterone;
- (549) Medrysone;
- (550) Mefenamic acid;
- (550.5) Mefloquine;

- (551) Megestrol;
- (552) Meglumine;
- (552.5) Meloxicam;
- (553) Melphalan;
- (553.5) Memantine;
- (554) Menadiol;
- (555) Menadione;
- (556) Meningococcal vaccine;
- (557) Menotropins;
- (558) Mepenzolate;
- (559) Mephenesin;
- (560) Mephentermine;
- (561) Mephenytoin;
- (562) Mepivacaine;
- (562.5) Mepolizumab;
- (563) Meprednisone;
- (563.5) Mequinol;
- (564) Meralluride;
- (565) Mercaptomerin;
- (566) Mercaptopurine;
- (567) Mercury bichloride — See exceptions;
- (567.1) Meropenem;
- (567.2) Mersalyl;
- (567.3) Mesalamine;
- (567.5) Mesna;
- (568) Mesoridazine;
- (569) Mestranol;
- (570) Metaproterenol;
- (571) Metaraminol;
- (572) Metaxalone;
- (572.5) Metformin;

- (573) Methacholine;
- (574) Methacycline;
- (575) Methallenestril;
- (576) Reserved;
- (577) Reserved;
- (578) Methantheline;
- (579) Methazolamide;
- (580) Methdilazine;
- (581) Methenamine hippurate;
- (582) Methenamine mandelate;
- (583) Methenamine sulfosalicylate;
- (584) Methicillin;
- (585) Methimazole;
- (586) Methiodal;
- (587) Methionine;
- (588) Methixene;
- (589) Methocarbamol;
- (590) Methotrexate;
- (591) Methotrimeprazine;
- (592) Methoxamine;
- (593) Methoxsalen;
- (594) Methoxyflurane;
- (595) Methoxyphenamine;
- (595.5) Methoxy polyethylene glycol-epoetin beta;
- (596) Methscopolamine;
- (597) Methsuximide;
- (598) Methyclothiazide;
- (599) Methylandrostenediol;
- (600) Methylatropine;
- (601) Methyldopa;
- (602) Methyldopate;

- (603) Methylene blue, Oral;
- (604) Methylergonovine;
- (604.5) Methylnaltrexone;
- (605) Methylprednisolone;
- (606) Reserved;
- (607) Methysergide;
- (608) Metoclopramide;
- (609) Metocurine iodide injection;
- (610) Metolazone;
- (611) Metoprolol;
- (611.5) Metreleptin;
- (612) Metrizamide;
- (612.5) Metrizoate;
- (613) Metronidazole;
- (614) Metyrapone;
- (615) Metyrosine;
- (615.01) Mexiletine;
- (615.1) Mezlocillin;
- (615.6) Mibefradil;
- (615.9) Micafungin;
- (616) Miconazole — See exceptions;
- (617) Microfibrillar collagen hemostat;
- (617.1) Midodrine;
- (617.2) Midostaurin;
- (617.22) Midubosathol;
- (617.3) Mifepristone;
- (617.35) Migalastat;
- (617.4) Miglitol;
- (617.44) Miglustat;
- (617.47) Milnacipran;
- (617.5) Milrinone;

(617.7) Miltefosine;
(618) Minocycline;
(619) Minoxidil — See exceptions;
(619.05) Mipomersen;
(619.1) Mirabegron;
(619.2) Mirikizumab-mrkz;
(619.3) Mirtazapine;
(619.4) Mirvetuximab soravtansine-gynx;
(619.5) Misoprostol;
(619.7) Mitapivat;
(620) Mithramycin;
(621) Mitomycin;
(622) Mitotane;
(622.3) Mitoxantrone;
(622.5) Mivacurium;
(622.6) Mobocertinib;
(622.7) Moexipril;
(622.8) Mogamulizumab;
(623) Molindone;
(623.2) Momelotinib;
(623.5) Mometasone — See exceptions;
(624) Monobenzene;
(624.1) Monooctanoin;
(624.5) Montelukast;
(624.7) Moricizine;
(625) Morrhuate;
(625.05) Mosunetuzumab-axgb;
(625.07) Motixafortide;
(625.1) Moxalactam;
(625.2) Moxetumomab pasudotox-tdfk;
(625.3) Moxidectin;

- (625.5) Moxifloxacin;
- (626) Mumps virus vaccines;
- (626.5) Mupirocin;
- (627) Mushroom spores which, when mature, contain either psilocybin or psilocin;
- (627.5) Mycophenolate;
- (628) N-acetyl-1-cysteine;
- (629) N. cattarhalis antigen;
- (629.5) Nabumetone;
- (630) Nadolol;
- (630.5) Nafarelin;
- (631) Nafcillin;
- (631.5) Naftifine;
- (632) Nalbuphine;
- (632.1) Naldemedine;
- (633) Reserved;
- (634) Nalidixic acid;
- (634.5) Nalmefene;
- (634.7) Naloxegol;
- (635) Naloxone — See exceptions;
- (635.1) Naltrexone;
- (636) Reserved;
- (637) Naphazoline — See exceptions;
- (638) Naproxen — See exceptions;
- (638.3) Naratriptan;
- (638.4) Natalizumab;
- (638.43) Naxitamab-gqgk;
- (638.45) Nebivolol;
- (638.47) Necitumumab;
- (638.5) Nedocromil;
- (638.6) Nedosiran;

- (638.7) Nefazodone;
- (638.75) Nelarabine;
- (638.8) Nelfinavir;
- (638.9) Nemolizumab-ilto;
- (639) Neomycin — See exceptions;
- (640) Neostigmine;
- (640.1) Nepafenac;
- (640.11) Neratinib maleate;
- (640.2) Nesiritide;
- (640.25) Netarsudil;
- (640.3) Netilmicin;
- (640.35) Netupitant;
- (640.4) Nevirapine;
- (640.5) Niacinamide — See exceptions;
- (640.7) Nicardipine;
- (640.8) Niclosamide;
- (641.1) Nicotine resin complex (polacrilex) — See exceptions;
- (641.15) Nicotine transdermal system — See exceptions;
- (642) Nicotiny alcohol;
- (642.1) Nifedipine;
- (643) Nifuroximine;
- (643.5) Nifurtimox;
- (644) Nikethamide;
- (644.3) Nilotinib;
- (644.4) Nilutamide;
- (644.5) Nimodipine;
- (644.6) Nintedanib;
- (644.61) Niraparib;
- (644.63) Nirmatrelvir;
- (644.64) Nirogacestat;
- (644.65) Nirsevimab-alip;

- (644.7) Nisoldipine;
- (644.72) Nitazoxanide;
- (644.8) Nitisinone;
- (644.9) Nitric oxide — for use in humans;
- (645) Nitrofurantoin;
- (646) Nitrofurazone;
- (647) Nitroglycerin;
- (648) Nitroprusside — See exceptions;
- (648.3) Nitrous oxide — See exceptions;
- (648.5) Nivolumab;
- (648.6) Nizatidine — See exceptions;
- (649) Nogapendekin alfa inbakicept-pmln;
- (649.1) Nomifensine maleate;
- (650) Nonoxynol — See exceptions;
- (651) Norepinephrine;
- (652) Norethindrone;
- (653) Norethynodrel;
- (653.5) Norfloxacin;
- (654) Norgestrel — See exceptions;
- (655) Normal serum albumin, Human;
- (656) Nortriptyline;
- (657) Nositol;
- (658) Novobiocin;
- (658.7) Nusinersen;
- (659) Nux vomica;
- (660) Nylidrin;
- (661) Nystatin;
- (661.02) Obecabtagene autoleucel;
- (661.03) Obeticholic acid;
- (661.05) Obiltoxaximab;
- (661.1) Obinutuzumab;

- (661.15) Ocilizumab;
- (661.2) Ocrelizumab;
- (661.3) Ocriplasmin;
- (661.5) Octreotide acetate;
- (661.55) Odesivimab-ebgn;
- (661.57) Odevixibat;
- (661.6) Ofatumumab;
- (661.7) Ofloxacin;
- (661.8) Olanzapine;
- (661.9) Olaparib;
- (661.96) Olaratumab;
- (662) Old tuberculin;
- (663) Oleandomycin;
- (663.03) Olezarsen;
- (663.05) Olipudase alfa;
- (663.1) Olmesartan;
- (663.15) Olodaterol;
- (663.2) Olopatadine — See exceptions;
- (663.3) Olsalazine Sodium;
- (663.32) Olutasidenib;
- (663.35) Omacetaxine mepesuccinate;
- (663.355) Omadacycline;
- (663.36) Omalizumab;
- (663.365) Omaveloxolone;
- (663.37) Ombitasvir;
- (663.4) Omega-3-acid;
- (663.5) Omeprazole — See exceptions;
- (663.55) Omidenepag isopropyl;
- (663.57) Omidubicel-only;
- (663.6) OnabotulinumtoxinA;
- (663.7) Ondansetron;

- (663.71) Opicapone;
- (663.73) Oritavancin;
- (663.75) Orlistat — See exceptions;
- (664) Orphenadrine;
- (665) Orthiodobenzoic acid;
- (665.5) Oseltamivir;
- (665.53) Osilodrostat;
- (665.55) Osimertinib;
- (665.6) Ospemifene;
- (665.65) Oteseconazole;
- (665.7) Ovine hyaluronidase;
- (666) Oxacillin;
- (666.4) Oxaliplatin;
- (666.6) Oxamniquine;
- (667) Oxaprozin;
- (667.5) Oxcarbazepine;
- (668) Oxethazaine;
- (668.5) Oxiconazole;
- (669) Oxolinic acid;
- (669.1) Oxprenolol;
- (670) Oxtriphylline;
- (671) Oxybutynin — See exceptions;
- (672) Oxygen for human use — See exceptions;
- (673) Oxymetazoline;
- (674) Oxyphenbutazone;
- (675) Oxyphencyclimine;
- (676) Oxyphenisatin;
- (677) Oxyphenonium;
- (678) Oxyquinoline;
- (679) Oxytetracycline;
- (680) Oxytocin;

(680.1) Ozanimod;
(680.3) Ozenoxacin;
(680.5) Ozogamicin;
(681) P-nitrosulfathiazole;
(681.3) Paclitaxel;
(681.32) Pacritinib;
(681.33) Pafolacianine;
(681.35) Palbociclib;
(681.4) Palifermin;
(681.45) Paliperidone;
(681.5) Palonosetron;
(681.55) Palopegteriparatide;
(681.6) Palovarotene;
(681.7) Pamidronate;
(682) Pancreatin dornase;
(683) Pancreatic enzyme;
(684) Pancrelipase;
(685) Pancuronium;
(685.5) Panidronate;
(685.6) Panitumumab;
(685.65) Panobinostat;
(685.7) Pantoprazole;
(686) Papaverine;
(687) Paramethadione;
(688) Paramethasone;
(689) Paranitrosulfathiazole;
(690) Parathyroid injection;
(691) Pargyline;
(691.5) Paricalcitol;
(691.7) Paritaprevir;
(692) Paromomycin;

- (692.2) Paroxetine;
- (692.25) Pasireotide;
- (692.28) Pasireotide;
- (692.29) Patiromer;
- (692.295) Patisiran;
- (692.3) Pazopanib;
- (692.4) Pegademase bovine;
- (692.5) Pegaspargase;
- (692.505) Pegcetacoplan;
- (692.51) Pegfilgrastim;
- (692.513) Peginesatide;
- (692.515) Peginterferon;
- (692.517) Pegloticase;
- (692.5175) Pegulicianine;
- (692.518) Pegunigalsidase alfa-iwxj;
- (692.519) Pegvaliase-pqpz;
- (692.52) Pegvisomant;
- (692.53) Pembrolizumab;
- (692.54) Pemetrexed;
- (692.545) Pemigatinib;
- (692.55) Pemirolast;
- (692.6) Penbutolol;
- (692.8) Penciclovir;
- (693) Penicillamine;
- (694) Penicillin;
- (695) Penicillin G;
- (696) Penicillin O;
- (697) Penicillin V;
- (698) Penicillinase;
- (699) Pentaerythritol tetranitrate;
- (700) Pentagastrin;

- (700.1) Pentamidine isethionate;
- (701) Pentapiperide;
- (701.5) Pentetate calcium trisodium;
- (701.7) Pentetate zinc trisodium;
- (702) Penthienate;
- (703) Pentolinium;
- (703.03) Pentosan;
- (703.05) Pentostatin;
- (703.1) Pentoxifylline;
- (703.4) Pentylenetetrazol;
- (703.42) Peramivir;
- (703.45) Perflexane;
- (703.5) Perflubron;
- (703.6) Perfluoroalkylpolyether;
- (703.63) Perfluorohexyloctane;
- (703.65) Perflutren;
- (703.7) Pergolide;
- (704) Perindopril;
- (704.1) Permethrin — See exceptions;
- (705) Perphenazine;
- (706) Pertussis immune globulin, Human;
- (706.5) Pertuzumab;
- (706.7) Pexidartinib;
- (707) Phenacemide;
- (708) Phenaglycodol;
- (709) Phenaphthazine;
- (710) Phenazopyridine — See exceptions;
- (711) Phenelzine;
- (712) Phenethicillin;
- (713) Phenformin;
- (714) Phenindamine;

- (715) Phenindione;
- (716) Pheniramine — See exceptions;
- (717) Phenitramin;
- (718) Phenothiazine derivatives;
- (719) Phenoxybenzamine;
- (720) Phenoxymethyl penicillin;
- (721) Phenuprocoumon;
- (722) Phensuximide;
- (723) Phentolamine;
- (724) Phenylbutazone;
- (725) Phenylmercuric acetate;
- (726) Phenylmercuric nitrate;
- (726.5) Phenylpropanolamine;
- (727) Phenyltoloxamine dihydrogen citrate;
- (727.2) Phenytoin;
- (728) Phthalylsulfacetamide;
- (729) Phthalylsulfathiazole;
- (730) Physostigmine;
- (731) Phytonadione;
- (731.01) Pibrentasvir;
- (731.05) Piflufolastat F 18;
- (732) Pilocarpine;
- (732.1) Pimecrolimus;
- (732.2) Pimozide;
- (732.3) Pinacidil;
- (732.7) Pindolol;
- (732.8) Pioglitazone;
- (733) Pipazethate;
- (733.5) Pipecuronium;
- (734) Pipenzolate;
- (735) Piperacetazine;

- (735.1) Piperacillin;
- (736) Piperazine;
- (737) Piperidolate;
- (738) Piperocaine;
- (739) Pipobraman;
- (740) Pipradrol;
- (740.05) Pirbuterol;
- (740.07) Pirfenidone;
- (740.1) Piroxicam;
- (740.3) Pirtobrutinib;
- (740.5) Pitavastatin;
- (740.7) Pitolisant;
- (741) Plague vaccine;
- (742) Plasma protein fraction;
- (742.03) Plasminogen, human-tvmh;
- (742.05) Plazomicin;
- (742.1) Plecanatide;
- (742.3) Plerixafor;
- (742.5) Plicamycin;
- (743) Pneumococcal vaccine;
- (743.3) Podofilox;
- (743.5) Podophyllotoxin;
- (744) Poison ivy extract;
- (745) Poison ivy oak extract;
- (746) Poison ivy oak, sumac extract;
- (746.5) Polatuzumab vedotin-piiq;
- (747) Poldine methysulfate;
- (747.4) Polidocanol;
- (748) Poliomyelitis vaccine;
- (749) Poliovirus vaccine, Live, Oral, All;
- (750) Polyestradiol;

- (751) Polymyxin B — See exceptions;
- (751.5) Polytetrafluoroethylene;
- (752) Polythiazide;
- (752.05) Pomalidomide;
- (752.1) Ponatinib;
- (752.15) Ponesimod;
- (752.2) Poractant alfa;
- (752.5) Porfimer;
- (752.7) Posaconazole;
- (753) Posterior pituitary;
- (754) Potassium acetate injection;
- (755) Potassium acid phosphate — See exceptions;
- (756) Potassium p-aminobenzoate — See exceptions;
- (757) Potassium aminosalicylate — See exceptions;
- (758) Potassium arsenite — See exceptions;
- (759) Potassium bicarbonate — See exceptions;
- (760) Potassium carbonate — See exceptions;
- (761) Potassium chloride — See exceptions;
- (762) Potassium citrate — See exceptions;
- (763) Potassium gluconate — See exceptions;
- (764) Potassium hetacillin;
- (765) Potassium iodide — See exceptions;
- (766) Reserved;
- (767) Potassium permanganate — See exceptions;
- (768) Povidone — Iodine — See exceptions;
- (768.3) Pozelimab-bbfg;
- (768.5) PrabotulinumtoxinA-xvfs;
- (768.8) Pralatrexate;
- (769) Pralidoxime;
- (769.1) Pralsetinib;
- (769.2) Pramipexole;

- (769.3) Pramlintide;
- (769.33) Prasterone;
- (769.35) Prasugrel;
- (769.4) Pravastatin;
- (769.7) Praziquantel;
- (770) Prazosin;
- (770.5) Prednicarbate;
- (771) Prednisolone;
- (772) Prednisone;
- (772.5) Pretomanid;
- (773) Prilocaine;
- (774) Primaquine;
- (775) Primidone;
- (776) Probenecid;
- (777) Probucol;
- (778) Procainamide;
- (779) Procaine;
- (780) Procaine penicillin;
- (781) Procaine penicillin G;
- (782) Procarbazine;
- (783) Prochlorperazine;
- (784) Procyclidine;
- (785) Progesterone;
- (785.5) Proguanil;
- (786) Promazine;
- (787) Promethazine;
- (788) Promethestrol;
- (788.5) Propafenone;
- (789) Propantheline;
- (790) Proparacaine;
- (791) Propenpyridamine — See exceptions;

- (792) Propiolactone;
- (793) Propiomazine;
- (794) Propoxycaïne;
- (795) Propranolol;
- (795.5) Propylhexedrine;
- (796) Propylparaben;
- (797) Propylthiouracil;
- (798) Protamine sulfate injection;
- (799) Protein hydrolysate injection;
- (800) Protein, Foreign injection;
- (801) Proteolytic enzyme;
- (801.5) Prothrombin complex concentrate, human-lans;
- (802) Protirelin;
- (803) Protokylol;
- (804) Protoveratrine A and B;
- (805) Protriptyline;
- (805.3) Prucalopride;
- (805.5) Prussian blue;
- (806) Reserved;
- (807) Pseudomonas polysaccharide complex;
- (808) P-ureidobenzenearsonic acid;
- (809) Purified protein derivatives of tuberculin;
- (810) Pyrantel;
- (811) Pyrazinamide;
- (812) Pyrazolon;
- (813) Pyridostigmine;
- (814) Pyrimethamine;
- (815) Pyrrobutamine;
- (816) Pyrvinium;
- (816.5) Quetiapine;
- (817) Quinacrine;

- (817.5) Quinapril;
- (818) Quinestrol;
- (819) Quinethazone;
- (820) Quinidine;
- (821) Quinine hydrochloride;
- (822) Quinine and urea hydrochloride;
- (822.3) Quinupristin;
- (822.4) Quizartinib;
- (822.5) Rabeprazole;
- (823) Rabies anti-serum;
- (824) Rabies immune globulin, Human;
- (825) Rabies vaccine;
- (826) Radio-iodinated compounds;
- (827) Radio-iodine;
- (828) Radio-iron;
- (829) Radioisotopes;
- (830) Radiopaque media;
- (831) Ragweed pollen extract;
- (831.02) Raloxifene;
- (831.03) Raltegravir;
- (831.04) Ramelteon;
- (831.05) Ramipril;
- (831.06) Ramucirumab;
- (831.07) Ranibizumab;
- (831.1) Ranitidine — See exceptions;
- (831.3) Ranolazine;
- (831.5) Rapacuronium;
- (831.7) Rasagiline;
- (832) Rauwolfia serpentina;
- (832.05) Ravulizumab;
- (832.1) Raxibacumab;

- (832.2) Reboparhamil;
- (832.5) Regadenoson;
- (832.7) Regorafenib;
- (832.8) Relatlimab-rmbw;
- (832.9) Relebactam;
- (832.95) Relugolix;
- (832.97) Remdesivir;
- (832.98) Repotrectinib;
- (833) Rescinnamine;
- (834) Reserpine;
- (835) Reserpine alkaloids;
- (835.5) Reslizumab;
- (835.7) Resmetirom;
- (836) Resorcinol monoacetate — See exceptions;
- (836.1) Respiratory syncytial virus vaccine;
- (836.3) Retapamulin;
- (836.4) Retifanlimab-dlwr;
- (836.5) Retinoic acid, all-trans;
- (836.7) Revefenacin;
- (836.75) Revumenib;
- (836.8) Rezafungin;
- (837) Rhus toxicodendron antigen;
- (838) Rh D immune globulin, Human;
- (838.5) Ribavirin;
- (838.6) Ribociclib;
- (839) Riboflavin — See exceptions;
- (840) Ricinoleic acid;
- (840.5) Rifabutin;
- (841) Reserved;
- (842) Rifampin;
- (842.05) Rifamycin;

(842.1) Rifapentine;
(842.15) Rifaximin;
(842.17) Rilonacept;
(842.18) Rilpivirine;
(842.2) Riluzole;
(842.4) Rimantadine;
(842.5) Rimegepant;
(842.7) Rimexolone;
(843) Ringer's injection;
(843.1) Riociguat;
(843.13) Ripretinib;
(843.15) Risankizumab-rzaa;
(843.17) Risdiplam;
(843.2) Risedronate;
(843.3) Risperidone;
(843.4) Ritlecitinib;
(843.7) Ritodrine;
(843.8) Ritonavir;
(843.82) Rituximab;
(843.825) Rivaroxaban;
(843.83) Rivastigmine;
(843.9) Rizatriptan;
(844) Rocky mountain spotted fever vaccine;
(844.5) Rocuronium;
(844.7) Rofecoxib;
(844.75) Roflumilast;
(844.8) Rolapitant;
(845) Rolitetracycline;
(845.1) Romidepsin;
(845.15) Romiplostim;
(845.2) Romosozumab-aqqg;

- (845.25) Ropeginterferon alfa-2b-njft;
- (845.3) Ropinirole;
- (845.5) Ropivacaine;
- (845.7) Rosiglitazone;
- (845.8) Rosuvastatin;
- (845.9) Rotavirus vaccine;
- (845.95) Rotigotine;
- (846) Rotoxamine;
- (846.3) Rozanolixizumab-noli;
- (846.5) RSVIGIV;
- (847) Rubella and mumps virus vaccine;
- (848) Rubella virus vaccine;
- (848.2) Rucaparib;
- (848.5) Rufinamide;
- (849) Rutin — See exceptions;
- (849.3) Sacituzumab govitecan-hziy;
- (849.5) Sacrosidase;
- (849.7) Sacubitril;
- (849.8) Saffinamide;
- (850) Salicylazosulfapyridine;
- (850.5) Salmeterol;
- (851) Salmonella typhosa, Killed;
- (851.03) Samarium SM 153 lexidronam;
- (851.035) Samidorphan;
- (851.04) Saneromazile;
- (851.045) Sapropterin;
- (851.05) Saquinavir;
- (851.1) Saralasin acetate;
- (851.15) Sarecycline;
- (851.2) Sarilumab;
- (851.5) Satralizumab-mwge;

- (851.7) Saxagliptin;
- (852) Scopolamine;
- (852.05) Sebelipase;
- (852.06) Secnidazole;
- (852.1) Secretin;
- (852.4) Secukinumab;
- (852.5) Segesterone acetate;
- (852.55) Seladelpar;
- (852.6) Selegiline;
- (853) Selenium sulfide — See exceptions;
- (853.5) Selenomethionine;
- (853.7) Selexipag;
- (853.8) Selinexor;
- (853.85) Selpercatinib;
- (853.87) Selumetinib;
- (853.9) Semaglutide;
- (854) Senecio cineraria extract ophthalmic solution;
- (855) Senega fluid extract;
- (855.3) Seractide acetate;
- (855.5) Sermorelin acetate;
- (855.6) Sertaconazole;
- (855.7) Sertraline;
- (855.73) Setmelanotide;
- (855.74) Sevelamer;
- (855.8) Sevoflurane;
- (855.85) Sildenafil;
- (855.9) Silodosin;
- (855.95) Siltuximab;
- (856) Silver nitrate ophthalmic solutions or suspensions;
- (857) Silver sulfadiazine cream;
- (857.1) Simeprevir;

- (857.3) Simethicone coated cellulose suspension;
- (857.5) Simvastatin;
- (858) Sincalide;
- (858.3) Sinecatechins;
- (858.4) Siponimod;
- (858.5) Sirolimus;
- (858.7) Sitagliptin;
- (859) Sitosterols;
- (860) Solutions for injections, All;
- (860.5) Smallpox and mpox (vaccinia) vaccine;
- (861) Smallpox vaccine;
- (862) Sodium acetate injection;
- (863) Sodium acetrizoate;
- (864) Sodium ascorbate injection;
- (865) Sodium biphosphate — See exceptions;
- (866) Sodium cacodylate;
- (867) Sodium chloride injection — See exceptions;
- (868) Sodium dehydrocholate;
- (869) Sodium dextrothyroxine;
- (870) Sodium estrone;
- (871) Sodium fluorescein — See exceptions;
- (872) Sodium fluoride — See exceptions;
- (873) Sodium iothalamate;
- (873.5) Sodium nitroprusside;
- (873.7) Sodium phenylbutyrate;
- (873.8) Sodium picosulfate;
- (874) Sodium polystyrene sulfonate;
- (875) Sodium propionated vaginal cream;
- (876) Sodium sulfacetamide;
- (877) Sodium sulfadiazine;
- (878) Sodium sulfobromophthalein;

- (879) Sodium sulfoxone;
- (880) Sodium tetradecyl;
- (880.5) Sodium thiosulfate;
- (881) Sodium tyropanoate;
- (881.01) Sodium zirconium cyclosilicate;
- (881.03) Sofosbuvir;
- (881.04) Sofpironium;
- (881.05) Solifenacin;
- (881.07) Somapacitan-beco;
- (881.1) Somatrem;
- (881.5) Somatrogon-ghla;
- (882) Somatropin;
- (882.3) Sonidegib;
- (882.5) Sorafenib;
- (883) Sorbus extract;
- (883.3) Sotagliflozin;
- (883.5) Sotalol;
- (883.55) Sotatercept-csrk;
- (883.6) Sotorasib;
- (883.8) Sparfloxacin;
- (883.9) Sparsentan;
- (884) Sparteine;
- (885) Spectinomycin;
- (885.3) Spesolimab-sbzo;
- (885.5) Spinosad;
- (886) Spirapril;
- (887) Spironolactone;
- (888) Staphage lysate bacterial antigen;
- (889) Staphylococcus and streptococcus vaccine;
- (890) Staphylococcus toxoid;
- (890.5) Stavudine;

- (891) Stibophen;
- (892) Stinging insect antigens — Combined;
- (892.5) Stiripentol;
- (893) Stockes expectorant;
- (894) Stramonium;
- (895) Streptococcus antigen;
- (896) Streptokinase-streptodornase;
- (897) Streptomycin;
- (898) Strontium — See exceptions;
- (899) Strophanthin-G;
- (900) Strychnine — See exceptions;
- (901) Succimer;
- (902) Succinylcholine;
- (903) Succinylsulfathiazole;
- (903.1) Sucralfate;
- (903.15) Sucroferric oxyhydroxide;
- (903.17) Sugammadex;
- (903.18) Sulbactam;
- (903.2) Sulconazole;
- (904) Sulfabenzamide vaginal preparations;
- (905) Sulfacetamide;
- (906) Sulfachlorpyridazine;
- (907) Sulfacytine;
- (908) Sulfadiazine;
- (909) Sulfadimethoxine;
- (909.1) Sulfadoxine;
- (910) Sulfaethidole;
- (911) Sulfaguanidine;
- (912) Sulfamerazine;
- (913) Sulfameter;
- (914) Sulfamethazine;

- (915) Sulfamethizole;
- (916) Sulfamethoxazole;
- (917) Sulfamethoxypyridazine;
- (918) Sulfanilamide;
- (919) Sulfaphenazole;
- (920) Reserved;
- (921) Sulfapyridine;
- (922) Sulfasalazine;
- (922.5) Sulfathiazole;
- (923) Sulfinpyrazone;
- (924) Sulfisomidine;
- (925) Sulfisoxazole;
- (926) Sulfur thioglycerol;
- (927) Sulindac;
- (927.3) Sulopenem etzadroxil;
- (927.5) Sumatriptan;
- (927.7) Sunitinib;
- (928) Superinone;
- (928.1) Suprofen;
- (929) Sutilains;
- (929.5) Sutimlimab-jome;
- (930) Syrosgingopine;
- (930.5) Tacrine;
- (930.7) Tacrolimus;
- (930.9) Tadalafil;
- (930.901) Tafamidis meglumine;
- (930.905) Tafasitamab-cxix;
- (930.91) Tafenoquine;
- (930.93) Tafluprost;
- (930.97) Taglilglucerase alfa;
- (930.975) Tagraxofusp-erzs;

- (930.976) Talazoparib;
- (930.98) Talimogene;
- (930.99) Talquetamab-tgvs;
- (931) Tamoxifen;
- (931.1) Tamsulosin;
- (931.15) Tapinarof;
- (931.17) Tarlatamab-dlle;
- (931.2) Tasimelteon;
- (931.203) Taurolidine;
- (931.205) Taurursodiol;
- (931.21) Tavaborole;
- (931.3) Tazarotene;
- (931.33) Tazemetostat;
- (931.35) Tazobactam;
- (931.37) Tbo-filgrastim;
- (931.4) Tebentafusp-tebn;
- (931.5) Technetium;
- (931.505) Teclistamab-cqyv;
- (931.51) Tecovirimat;
- (931.52) Tedizolid;
- (931.53) Teduglutide;
- (931.55) Tegaserod;
- (931.553) Telaprevir;
- (931.555) Telavancin;
- (931.56) Telbivudine;
- (931.57) Telithromycin;
- (931.6) Telmisartan;
- (931.61) Telotristat ethyl;
- (931.7) Temafloracin;
- (931.75) Temozolomide;
- (931.77) Temsirolimus;

- (931.79) Tenapanor;
- (931.8) Teniposide;
- (931.81) Teplizumab-mzwv;
- (931.82) Tepotinib;
- (931.83) Teprotumumab-trbw;
- (931.85) Terazosin;
- (931.9) Tenofovir;
- (931.95) Terbinafine — See exceptions;
- (932) Terbutaline;
- (932.05) Terconazole;
- (932.1) Terfenadine;
- (932.2) Teriflunomide;
- (932.3) Teriparatide;
- (932.5) Terlipressin;
- (933) Terpin hydrate with codeine;
- (934) Reserved;
- (935) Tesamorelin;
- (936) Tetanus and diphtheria toxoids;
- (937) Tetanus antitoxin;
- (938) Tetanus immune globulin;
- (939) Tetanus toxoids;
- (939.5) Tetrabenazine;
- (940) Tetracaine;
- (941) Tetracycline;
- (942) Tetraethylammonium chloride;
- (943) Tetrahydrozoline — See exceptions;
- (943.3) Tezacaftor;
- (943.4) Tezepelumab-ekko;
- (943.5) Thalidomide;
- (944) Thallous chloride;
- (945) Theobromide;

- (946) Theobromine magnesium oleate;
- (947) Theophylline — See exceptions;
- (948) Theophylline sodium glycinate;
- (949) Thiabendazole;
- (950) Thiamylal;
- (951) Thiethylperazine;
- (952) Thiopropazate;
- (953) Thioguanine;
- (954) Thioridazine;
- (955) Thiosalicylate;
- (956) Thiotepa;
- (957) Thiothixene;
- (958) Thiphenamil;
- (959) Thrombin;
- (960) Thyroglobulin;
- (961) Thyroid;
- (962) Thyrotropin;
- (963) Thyroxine;
- (964) Thyroxine fraction;
- (964.5) Tiagabine;
- (964.7) Ticagrelor;
- (965) Ticarcillin;
- (965.3) Tick-borne encephalitis vaccine;
- (965.5) Ticlopidine;
- (966) Ticrynafen;
- (966.3) Tigecycline;
- (966.5) Tildrakizumab;
- (966.6) Tiludronate;
- (967) Timolol;
- (967.1) Tinidazole;
- (967.2) Tinzaparin;

(967.3) Tioconazole — See exceptions;
(967.5) Tiopronin;
(967.55) Tiotropium;
(967.56) Tipiracil;
(967.57) Tipranavir;
(967.58) Tirbanibulin;
(967.6) Tirofiban;
(967.61) Tirzepatide;
(967.62) Tisagenlecleucel;
(967.625) Tislelizumab-jsgr;
(967.63) Tisotumab vedotin-tftv;
(967.67) Tivozanib;
(967.7) Tizanidine;
(968) Tobramycin;
(968.1) Tocainide;
(969) Tocamphyl;
(969.6) Tocilizumab;
(969.8) Tofacitinib;
(969.9) Tofersen;
(970) Tolazamide;
(971) Tolazoline;
(972) Tolbutamide;
(972.5) Tolcapone;
(973) Tolmetin;
(973.05) Tolterodine;
(973.07) Tolvaptan;
(973.1) Topiramate;
(973.3) Topotecan;
(973.4) Toremifene;
(973.45) Toripalimab-tpzi;
(973.5) Torsemide;

- (973.55) Tovorafenib;
- (973.6) Trabectedin;
- (973.65) Tralokinumab-ldrm;
- (973.7) Trametinib;
- (973.8) Trandolapril;
- (973.9) Tranexamic acid;
- (974) Tranylcypromine;
- (974.2) Trastuzumab;
- (974.4) Travoprost;
- (974.5) Trazodone;
- (974.6) Tremelimumab-actl;
- (974.7) Treprostinil;
- (975) Tretinoin;
- (976) Triamcinolone — See exceptions;
- (977) Triamterene;
- (978) Trichlormethiazide;
- (979) Trichloroacetic acid — See exceptions;
- (980) Trichloroethylene — See exceptions;
- (981) Trichlobisonium;
- (981.5) Triclabendazole;
- (982) Triclofos;
- (983) Tridihexethyl chloride;
- (983.1) Trientine;
- (984) Triethanolamine polypeptides;
- (985) Triethylenethiophosphoramide;
- (985.5) Trifarotene;
- (986) Trifluoperazine;
- (987) Triflupromazine;
- (988) Trifluridine;
- (988.5) Triheptanoin;
- (989) Trihexyphenidyl;

- (990) Triiodothyronine;
- (990.05) Trilaciclib;
- (990.1) Trilostane;
- (991) Trimeprazine;
- (992) Trimethadione;
- (993) Trimethaphan cansylate;
- (994) Trimethobenzamide;
- (995) Trimethoprim;
- (995.5) Trimetrexate;
- (996) Trimipramine;
- (997) Triolein;
- (998) Trioxsalen;
- (999) Tripelennamine — See exceptions;
- (1000) Triphenyltetrazolium;
- (1001) Triple sulfas;
- (1002) Triprolidine — See exceptions;
- (1002.5) Triptorelin;
- (1003) Trisulfapyrimidines;
- (1003.3) Trofinetide;
- (1003.5) Troglitazone;
- (1004) Troleandomycin;
- (1005) Trolnitrate;
- (1006) Tromethamine;
- (1007) Tropicamide;
- (1007.3) Trospium;
- (1007.5) Trovafloxacin;
- (1008) Trypsin;
- (1009) Trypsin-chymotrypsin;
- (1010) Tuaminoheptane;
- (1011) Tuberculin, Purified protein derivatives;
- (1012) Tuberculin tine test;

- (1013) Tuberculin, Old;
- (1014) Tubocurarine;
- (1014.5) Tucatinib;
- (1015) Tybamate;
- (1016) Typhoid and paratyphoid vaccine;
- (1017) Typhus vaccine;
- (1018) Tyropanoate;
- (1018.2) Ublituximab-xiiy;
- (1018.3) Ubrogapant;
- (1018.5) Ulapristal;
- (1018.7) Umbralisib;
- (1018.8) Umeclidinium;
- (1019) Undecoylium;
- (1019.5) Unoprostone;
- (1019.7) Upadacitinib;
- (1020) Uracil;
- (1021) Urea — See exceptions;
- (1021.1) Uridine;
- (1021.3) Urofollitropin;
- (1021.5) Ursodiol;
- (1021.6) Ustekinumab;
- (1021.61) Vaborbactam;
- (1021.65) Vadadustat;
- (1021.7) Valacyclovir;
- (1021.71) Valbenazine;
- (1021.8) Valdecobix;
- (1022) Valethamate;
- (1022.2) Valganciclovir;
- (1022.5) Valoctocogene roxaparvovec-rvox;
- (1023) Valproate;
- (1024) Valproic acid — See exceptions;

(1024.3) Valrubicin;
(1024.5) Valsartan;
(1024.8) Vamorolone;
(1025) Vancomycin;
(1025.2) Vandetanib;
(1025.3) Vanzacaftor;
(1025.5) Vardenafil;
(1025.7) Varenicline;
(1025.8) Varicella virus vaccine, Live;
(1026) Vasopressin;
(1027) VDRL antigen;
(1027.1) Vecuronium bromide;
(1027.2) Vedolizumab;
(1027.3) Velaglucerase;
(1027.4) Velmanase alfa-tycv;
(1027.5) Velnacrine;
(1027.53) Velpatasvir;
(1027.55) Vemuranfenib;
(1027.57) Venetoclax;
(1027.6) Venlafaxine;
(1027.7) Verapamil;
(1028) Veratrum viride;
(1028.5) Vericiguat;
(1029) Versenate;
(1029.5) Verteporfin;
(1029.6) Vestronidase alfa-vjbk;
(1029.8) Vibegron;
(1030) Vidarabine;
(1030.3) Vigabatrin;
(1030.4) Vilanterol;
(1030.5) Vilazodone;

- (1030.6) Viloxazine;
- (1030.7) Viltolarsen;
- (1031) Vinblastine;
- (1032) Vincristine;
- (1032.5) Vinorelbine;
- (1033) Vinyl ethyl — See exceptions;
- (1034) Viomycin;
- (1034.5) Vismodegib;
- (1035) Vitamin K;
- (1036) Vitamin B12 injection;
- (1037) Vitamine with fluoride;
- (1037.2) Voclosporin;
- (1037.23) Von Willebrand factor;
- (1037.27) Vonoprazan;
- (1037.3) Vorapaxar;
- (1037.4) Vorasidenib;
- (1037.5) Voriconazole;
- (1037.7) Vorinostat;
- (1037.8) Vortioxetine;
- (1037.83) Vosoritide;
- (1037.85) Voxelotor;
- (1037.9) Voxilaprevir;
- (1037.95) Vutrisiran;
- (1038) Warfarin;
- (1039) Wargarin;
- (1039.05) Xanomeline;
- (1039.1) Xylocaine;
- (1040) Yellow fever vaccine;
- (1041) Yohimbine;
- (1042) 4-chloro-3, 5-xyleneol — See exceptions;
- (1042.01) Zafirlukast;

- (1042.02) Zalcitabine;
- (1042.03) Zanamivir;
- (1042.035) Zanidatamab-hrii;
- (1042.04) Zanubrutinib;
- (1042.045) Zavegepant;
- (1042.047) Zenocutuzumab-zbco;
- (1042.05) Zidovudine;
- (1042.4) Zileuton;
- (1042.6) Zilucoplan;
- (1042.7) Zinc acetate — See exceptions;
- (1042.75) Ziprasidone;
- (1042.78) Ziv-aflibercept;
- (1042.79) Zolbetuximab-clzb;
- (1042.8) Zoledronic acid;
- (1042.9) Zolmitriptan;
- (1042.92) Zonisamide;
- (1042.95) Zoster vaccine recombinant, Adjuvanted;
- (1043) Devices that require a prescription:
 - (A) Cellulose, Oxadized, Regenerated (surgical absorbable hemostat) — See exceptions;
 - (B) Diaphragms for vaginal use;
 - (C) Hemodialysis solutions;
 - (D) Hemodialysis kits;
 - (E) Lippes loop intrauterine;
 - (F) Saf-T-Coil intrauterine device;
 - (G) Intrauterine devices, All;
 - (H) Absorbable hemostat;
 - (I) Gonorrhea test kit.

(b.1) A “restricted dangerous drug” means any other drug or substance declared by the General Assembly to have no medical use, which cannot be legally prescribed by a practitioner, and which cannot be manufactured, grown, produced, distributed, used, or otherwise pos-

sessed in this state; to include any of the following drugs, chemicals, or substances; salts, isomers, esters, ethers, or derivatives of such drugs, chemicals, or substances which have essentially the same pharmacological action; and all other salts, isomers, esters, ethers, and compounds of such drugs, chemicals, or substances unless specifically exempted, identified as “restricted dangerous drugs”:

(1) Salvinorin A; and

(2) *Salvia divinorum* — except as otherwise provided for in paragraph (4.3) of Code Section 16-13-72.

This subsection shall not prohibit a person from possessing a restricted dangerous drug for the purpose of conducting research approved by the federal Food and Drug Administration.

(c) The following are exceptions to and exemptions from subsection (b) of this Code section:

(0.5) Adapalene — when used with a strength up to 0.1 percent in a topical skin product;

(0.7) Alcaftadine — when used in a concentration of 0.25 percent or less in an ophthalmic solution;

(1) Atropine sulfate — where the oral dose is less than 1/200 gr. per unit;

(1.5) Azelastine hydrochloride — when used in a concentration of 0.15 percent or less in a nasal spray or nasal solution;

(2) Bacitracin cream or ointment for topical use;

(3) Belladonna or belladonna alkaloids when in combination with other drugs and the dosage unit is less than 0.1 mg. of the alkaloids or its equivalent;

(3.5) Bentoquatam — when used with a strength of 5 percent or less in topical preparations;

(4) Beta carotene — all forms occurring in food products or lotions;

(5) Bromelain, pancreatic enzymes, trypsin and bile extract — when labeled properly as digestive aids with appropriate dosage and in compliance with FDA labeling and restrictions;

(6) Brompheniramine — where a single dosage unit is 4 mg. or less but with no more than 3 mg. of the dextrorotary optical isomer of racemic brompheniramine per released dose;

(6.1) Budesonide — when used as a nasal spray in doses up to 32 mcg. per spray;

(6.2) Butenafine — when used with a strength of 1 percent or less as a topical preparation;

(6.4) Butoconazole — when used with a strength up to 2 percent in a vaginal preparation;

(6.45) Capsaicin — when in an external analgesic with concentration of 0.25 percent or less;

(6.5) Cetirizine — when a single dosage unit is either 1 mg. per 1 ml. or less or 10 mg. or less;

(6.7) Chlorhexadine — when used with a strength up to 4 percent in a topical skin product;

(7) Chlorpheniramine — where a single dosage unit is 12 mg. or less;

(7.1) Cimetidine — when a single dosage unit is 200 mg. or less;

(7.3) Clemastine — where a single dose is 1.34 mg. or less;

(7.5) Clotrimazole — when a single vaginal insert is 200 mg. or less or with a strength up to 2 percent in a topical skin, topical vaginal, or vaginal product;

(7.8) Cromolyn — when used as cromolyn sodium in a nasal solution of 4 percent or less in strength;

(7.9) Dexbrompheniramine — when a single dosage unit is 6 mg. or less;

(7.95) Diclofenac Sodium — When used with a strength of 1 percent or less in a topical gel;

(8) Diphenhydramine — up to 12.5 mg. in each 5 cc's when used in cough preparations and up to 50 mg. per single dose when used as a nighttime sleep aid or used as an antihistamine and labeled in compliance with FDA requirements;

(8.5) Docosanol — when used in 10 percent topical preparation to treat fever blisters, cold sores, or fever blisters and cold sores.

(9) Doxylamine succinate — where a single dosage form is 25 mg. or less and when labeled to be used as a nighttime sedative;

(9.3) Edetate — when used in any form other than an oral or parenteral;

(9.33) Epinephrine — when used in a device that delivers a metered spray of 0.125 mg. of epinephrine or less to provide temporary relief for symptoms of mild, intermittent asthma and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA);

(9.4) Esomeprazole — when a single dosage unit is 20 mg. or less;

- (9.5) Famotidine — when a single dosage unit is 20 mg. or less;
- (9.6) Fexofenadine — when packaged for distribution as an over-the-counter (OTC) drug product;
- (9.7) Fluoride — when used with a strength up to 1,500 parts per million in an oral care or dentifrice product;
- (9.75) Fluticasone — when available in a device that delivers a metered spray of 0.05 mg. and to be used for the temporary relief of symptoms due to hay fever or other upper respiratory allergies;
- (9.8) Glycine — when used with a strength up to 1.5 percent in an irrigation solution, when used in a topical skin product;
- (10) Hydrocortisone topical skin preparations up to 1 percent in strength;
- (11) Hydroxocobalamin, riboflavin, niacinamide, ergocalciferol (maximum of 400 I.U. per day), Folic acid (maximum of 0.4 mg. per day), and magnesium gluconate — when as a source of vitamins and dietary supplement but must bear such labels and adhere to such restrictions of FDA regulations;
 - (11.1) Ibuprofen — where a single dose is 200 mg. or less;
 - (11.6) Reserved;
- (12) Insulin — all injectable products which do not require a prescription drug order and bear a label which indicates “Rx Use Only” or are otherwise listed under subsection (b) of this Code section; and no injectable insulin product may be sold except by a pharmacy issued a permit by the State Board of Pharmacy or by a medical practitioner authorized to dispense medications;
 - (12.1) Ivermectin — When used with a strength of 0.5 percent or less in a topical lotion;
 - (12.3) Ketoconazole — when used with a strength of 1 percent or less in topical preparations;
 - (12.5) Ketoprofen — when a single dosage unit is 12.5 mg. or less;
 - (12.7) Ketotifen — when used with a strength of 0.025 percent or less in an ophthalmic solution;
 - (12.9) Lansoprazole — when a single dosage unit is 15 mg. or less;
 - (12.91) Levocetirizine — when a single dose unit is either 2.5 mg. per 5 ml. or less or 5 mg. or less;
 - (12.95) Levocetirizine dihydrochloride — when used in a single dose of 5 mg. or less;

(13) Lidocaine topical, 40 mg./gm. (4 percent) or less;

(13.5) Loperamide — where a single dose is either 1 mg. per 5 ml. or 2 mg. per dosage unit;

(13.7) Loratadine — when used in a single dose of 10 mg. or less, including doses used in combination with other drugs provided for under this subsection;

(14) Meclizine — 25 mg. or less;

(14.1) Miconazole — when used as antifungal powder or cream, or both, and containing not more than 4 percent of miconazole, or when used as a vaginal insert and containing not more than 1,200 mg. of miconazole;

(14.2) Minoxidil — when used with a strength of 5 percent or less in topical preparations;

(14.23) Mometasone — when used as mometasone furoate in a nasal spray in doses up to 50 mcg per spray;

(14.25) Naloxone — shall also be exempt from subsections (a) and (b) of this Code section when used for drug overdose prevention as follows:

(A) Nasal adaptor rescue kits containing a minimum of two prefilled 2 ml. luer-lock syringes with each containing 1 mg./ml. of naloxone;

(B) Prepackaged nasal spray rescue kits containing single-use spray devices with each containing a minimum of 4 mg./0.1 ml. of naloxone;

(C) Muscle rescue kits containing a 10 ml. multidose fliptop vial or two 1 ml. vials with a strength of 0.4 mg./ml. of naloxone when supplied by a dispenser or licensed distributor or wholesaler; or

(D) Prepackaged kits of two muscle autoinjectors with each containing a minimum of 0.4 mg./ml. of naloxone when supplied by a dispenser or licensed distributor or wholesaler;

(14.3) Naphazoline — when used in an ophthalmic solution in a concentration of 0.027 percent or less in combination with a pheniramine concentration of 0.315 percent or less;

(14.5) Naproxen — where a single dosage unit is 220 mg. or less;

(15) Neomycin sulfate ointment or cream for topical use;

(15.5) Nicotine resin complex (polacrilex) — when used as oral chewing gum where a single dose (piece of gum) is 4 mg. or less;

(15.55) Nicotine transdermal system — when used in a strength of 21 mg. or less per transdermal patch (transdermal delivery system);

(16) Nitrous oxide — air products suppliers shall not sell medical grade nitrous oxide to other than licensed practitioners or medical suppliers; industrial grade nitrous oxide shall only be sold when mixed with not less than 100 parts per million of sulfur dioxide and used as a fuel additive for combustion engines or when used in industrial laboratory equipment;

(16.3) Nizatidine — when a single dosage unit is 75 mg. or less;

(16.8) Nonoxynol — when used with a strength up to 12.5 percent or 1 gram per dose in a vaginal product;

(16.83) Norgestrel — 0.075 mg. tablet when used for the prevention of pregnancy;

(16.85) Olopatadine hydrochloride — When used with a strength of 0.7 percent or less in an ophthalmic solution;

(16.9) Omeprazole — when a single dosage unit is 20.6 mg. or less;

(16.92) Any opioid antagonist, as defined in Code Section 26-4-116.2, shall also be exempt from subsections (a) and (b) of this Code section when used for drug overdose prevention and when supplied by a dispenser or an authorized wholesale distributor;

(16.95) Orlistat — when a single dosage unit is 60 mg. or less;

(16.97) Oxybutynin — when a single dose is delivered as 3.9 mg. per day using a transdermal system patch;

(17) Oxygen — compressed oxygen which is not labeled “CAUTION: Federal law prohibits dispensing without prescription” or similar wording;

(17.3) Permethrin — when used as a topical preparation in a strength of 1 percent or less;

(17.5) Phenazopyridine — where a single dose is 100 mg. or less, as approved by the federal Food and Drug Administration;

(18) Pheniramine — when the oral dose is 25 mg. or less, or when used in an ophthalmic solution in a concentration of 0.315 percent or less in combination with a naphazoline concentration of 0.027 percent or less;

(19) Polymyxin B when in combination with other drugs in an ointment or cream for topical use;

(20) Any potassium electrolyte when manufactured for use as a dietary supplement, food additive for industrial, scientific, or commercial use, or when added to other drug products when the product is not intended as a potassium supplement but must bear such labels and adhere to such restrictions of FDA regulations;

(21) Povidone — Iodine solutions and suspensions;

(22) Reserved;

(23) Reserved;

(23.5) Ranitidine — when a single dosage unit is 150 mg. or less;

(24) Rutin — where the dosage unit is less than 60 mg.;

(25) Selenium sulfide suspension 1 percent or less in strength;

(25.05) Sodium chloride injection — when in quantities of 10 cc or less and used as a catheter flush solution to act by physically occupying space within a catheter and exerting pressure on the patient's circulating blood;

(25.1) Strychnine — when used in combination with other active ingredients in a rodent killer, and when not bearing a label containing the words "CAUTION: Federal law prohibits dispensing without prescription" or other similar wording;

(25.5) Terbinafine — when used with a strength of 1 percent or less in a topical antifungal cream;

(26) Tetrahydrozoline for ophthalmic or topical use;

(27) Theophylline preparations alone or in combination with other drugs prepared for and approved for OTC (over the counter) sale by FDA; example — tedral tablets (plain) or oral suspension;

(27.5) Tioconazole — when used with a strength of 1 percent or less in topical preparations or when used with a strength of 6.5 percent or less in vaginal preparations;

(27.7) Triamcinolone acetonide — when used in a nasal spray that delivers 55 mcg. per spray or less;

(28) Tripelennamine cream or ointment for topical use;

(28.5) Triprolidine — when a single dose is 5 mg. or less when combined in the same preparation as one or more other drug products for use as an antihistamine or decongestant or an antihistamine and decongestant;

(29) Urea — except when the manufacturer's label contains the wording "CAUTION: Federal law prohibits dispensing without prescription" or similar wording;

(29.5) Zinc acetate — when used in topical preparations;

(30) Any drug approved by FDA for animal use and the package does not bear the statement "CAUTION: Federal law prohibits dispensing without prescription" or similar wording; or

(31) Loperamide Oral Liquid (1.00 mg./5.00 ml.).

(d) The following list of compounds or preparations may be purchased without a prescription, provided the products are manufactured for industrial, scientific, or commercial sale or use, unless they are intended for human use or contain on the label "CAUTION: Federal law prohibits dispensing without prescription" or similar wording:

- (1) Aminosalicylate;
- (2) Aminosalicylate calcium;
- (3) Aminosalicylate potassium;
- (4) Aminosalicylate sodium;
- (5) Aminosalicylic acid;
- (6) Barium;
- (7) Beta-carotene;
- (8) Bismuth sodium tartrate;
- (9) Cadmium sulfide;
- (10) Calcium disodium edetate;
- (11) Cellulose, Oxadized, Regenerated;
- (12) Chlorabutanol;
- (13) Chloranil;
- (14) Chloroacetic acid;
- (15) Chloroform;
- (16) Colchicine;
- (17) Dapsone;
- (18) Dimethyl sulfoxide;
- (19) Disodium edetate;
- (20) Edetate disodium;
- (21) Ether;
- (22) Ethoxazene;
- (23) Ethyl chloride;
- (24) Fluoride;
- (25) Formaldehyde;
- (26) Gold thiosulfate;

- (27) Hexachlorophene;
- (28) Iodobenzoic acid;
- (29) Iopanoic acid;
- (30) Lindane;
- (31) Lithium carbonate;
- (32) Mandelic acid;
- (33) Mannitol;
- (34) Mercury bichloride;
- (35) Nitroprusside;
- (36) Potassium aminosalicylate;
- (37) Potassium p-aminobenzoate;
- (37.5) Potassium perchlorate;
- (38) Potassium permanganate;
- (39) Resorcinol monoacetate;
- (40) Selenium sulfide;
- (41) Sodium biphosphate;
- (42) Sodium fluorescein;
- (43) Sodium fluoride;
- (44) Strontium;
- (45) Trichloroacetic acid;
- (46) Trichloroethylene;
- (47) Valproic acid;
- (48) Vinyl ether;
- (49) 4-chloro-3, 5-xilenol.

(e) The State Board of Pharmacy may delete drugs from the dangerous drug list set forth in this Code section. In making such deletions the board shall consider, with respect to each drug, the following factors:

- (1) The actual or relative potential for abuse;
- (2) The scientific evidence of its pharmacological effect, if known;
- (3) The state of current scientific knowledge regarding the drug;
- (4) The history and current pattern of abuse, if any;

- (5) The scope, duration, and significance of abuse;
- (6) Reserved;
- (7) The potential of the drug to produce psychic or physiological dependence liability; and
- (8) Whether such drug is included under the federal Food, Drug, and Cosmetic Act, 52 Stat. 1040 (1938), 21 U.S.C. Section 301, et seq., as amended.

History.

Code 1933, § 79A-702, enacted by Ga. L. 1967, p. 296, § 1; Ga. L. 1972, p. 948, § 1; Ga. L. 1976, p. 631, § 1; Ga. L. 1978, p. 1668, § 5; Ga. L. 1979, p. 859, § 3; Ga. L. 1980, p. 1746, § 2; Ga. L. 1981, p. 557, § 2; Ga. L. 1982, p. 3, § 16; Ga. L. 1982, p. 2403, §§ 3-8, 20.; Ga. L. 1983, p. 3, § 13; Ga. L. 1983, p. 349, §§ 3-6; Ga. L. 1984, p. 22, § 16; Ga. L. 1984, p. 1019, §§ 3-5; Ga. L. 1985, p. 1219, §§ 8, 9; Ga. L. 1986, p. 1555, §§ 6, 7; Ga. L. 1987, p. 261, § 7; Ga. L. 1989, p. 233, §§ 7, 8; Ga. L. 1990, p. 640, §§ 2, 3; Ga. L. 1991, p. 312, § 2; Ga. L. 1992, p. 6, § 16; Ga. L. 1992, p. 1131, §§ 5-7; Ga. L. 1993, p. 590, §§ 4-7; Ga. L. 1994, p. 169, §§ 6, 7; Ga. L. 1994, p. 849, § 1; Ga. L. 1996, p. 356, §§ 3-5; Ga. L. 1997, p. 1311, §§ 6-10; Ga. L. 1998, p. 778, §§ 3-6; Ga. L. 1999, p. 81, § 16; Ga. L. 1999, p. 643, §§ 2-5; Ga. L. 2000, p. 1317, §§ 4-6; Ga. L. 2001, p. 816, §§ 4-6; Ga. L. 2003, p. 349, §§ 8-11; Ga. L. 2004, p. 488, §§ 4-7; Ga. L. 2005, p. 1028, §§ 2, 3/SB 89; Ga. L. 2006, p. 219, §§ 3-5/HB 1054; Ga. L. 2007, p. 47, § 16/SB 103; Ga. L. 2007, p. 605, §§ 3-5/HB 286; Ga. L. 2008, p. 169, §§ 6, 7, 8/HB 1090; Ga. L. 2009, p. 126, § 5/HB 368; Ga. L. 2010, p. 860, §§ 5, 6, 7/SB 353; Ga. L. 2010, p. 905, § 1/HB 1021; Ga. L. 2011, p. 656, §§ 7-10/SB 93; Ga. L. 2012, p. 40, § 5/SB 370; Ga. L. 2013, p. 71, §§ 3, 4, 5/HB 302; Ga. L. 2014, p. 217, §§ 6, 7/HB 835; Ga. L. 2014, p. 866, § 16/SB 340; Ga. L. 2015, p. 5, § 16/HB 90; Ga. L. 2015, p. 883, §§ 5, 6/HB 211; Ga. L. 2016, p. 798, §§ 5-7, 8/HB 783; Ga. L. 2016, p. 864, § 16/HB 737; Ga. L. 2017, p. 14, §§ 9-11/HB 231; Ga. L. 2017, p. 22, §§ 2, 3/SB 121; Ga. L. 2017, p. 319, §§ 1-3, 1-4/HB 249; Ga. L. 2017, p. 774, § 16/HB 323; Ga. L. 2018, p. 314, §§ 6-9/HB 830; Ga. L. 2019, p. 820, §§ 4-12/HB 483; Ga. L. 2020, p. 16,

§§ 2-4/HB 759; Ga. L. 2020, p. 55, § 1/SB 372; Ga. L. 2020, p. 493, § 16/SB 429; Ga. L. 2021, p. 386, §§ 8-10/HB 367; Ga. L. 2021, p. 922, § 16/HB 497; Ga. L. 2022, p. 803, §§ 7-9/HB 963; Ga. L. 2023, p. 137, §§ 5-7/HB 332, effective May 1, 2023; Ga. L. 2024, p. 161, §§ 7-11/HB 1326, effective April 22, 2024; Ga. L. 2024, p. 293, § 1/SB 395, effective July 1, 2024; Ga. L. 2025, p. 200, §§ 5, 6/HB 473, effective May 1, 2025; Ga. L. 2025, p. 1029, § 16(10)/SB 153, effective July 1, 2025.

Amendments.

The first 2025 amendment, effective May 1, 2025, added paragraphs (b)(12.8), (b)(17.07), (b)(62.45), (b)(63.3), (b)(68.133), (b)(69.23), (b)(153.65), (b)(206.6), (b)(213.2), (b)(216.5), (b)(217.3), (b)(220.5), (b)(238.5), (b)(256.58), (b)(256.8), (b)(316.45), (b)(331.0504), (b)(331.0506), (b)(331.0515), (b)(332.3), (b)(332.73), (b)(332.75), (b)(380.45), (b)(402.3), (b)(415.005), (b)(464.9), (b)(466.8), (b)(469.02), (b)(487.09), (b)(512.1), (b)(513.03), (b)(513.07), (b)(513.79), (b)(514.3), (b)(520.1), (b)(530.3), (b)(540.47), (b)(540.8), (b)(638.9), (b)(649), (b)(661.02), (b)(663.03), (b)(681.55), (b)(692.5175), (b)(835.7), (b)(836.75), (b)(852.55), (b)(860.5), (b)(881.04), (b)(883.55), (b)(927.3), (b)(931.17), (b)(967.625), (b)(973.55), (b)(1021.65), (b)(1025.3), (b)(1037.4), (b)(1039.05), (b)(1042.035), (b)(1042.047), (b)(1042.79), and subparagraph (b)(59)(ZZ.5).

The second 2025 amendment, effective July 1, 2025, part of an Act to revise, modernize, and correct the Code, substituted “Anthrax vaccine adsorbed, Adjuvanted” for “Anthrax Vaccine Adsorbed, Adjuvanted” in paragraph (b)(57.5), substituted “House dust mite allergen extract” for “House Dust Mite Allergen Extract” in subparagraph (b)(59)(BB.5),

substituted “Chikungunya vaccine, Live” for “Chikungunya Vaccine, Live” in paragraph (b)(160.5), substituted “Coagulation Factor X, Human” for “Coagulation Factor X, (human)” in paragraph (b)(206.7), substituted “Dengue tetravalent vaccine, Live” for “Dengue Tetravalent Vaccine, Live” in paragraph (b)(247.4), substituted “Dornase alpha” for “Dornase Alpha” in paragraph (b)(317.3), substituted “Ebola Zaire vaccine, Live” for “Ebola Zaire Vaccine, Live” in paragraph (b)(328.3), deleted paragraph (b)(361.5), which read: “Reserved;”, substituted “Ferric hexacyanoferrate” for “Ferric Hexacyanoferrate” in paragraph (b)(383.15), deleted paragraph (b)(386.3), which read: “Reserved;”, substituted “Gomenol solution” for “Gomenol Solution” in paragraph (b)(425), substituted “Halobetasol propionate” for “Halobetasol Propionate” in paragraph (b)(433.5), substituted “Human papillomavirus 9-valent vaccine, Recombinant” for “Human Papillomavirus 9-valent Vaccine, Recombinant” in paragraph (b)(446.2), deleted paragraph (b)(509.7), which read: “Reserved;”, deleted para-

graph (b)(512.691), which read: “Reserved;”, deleted paragraph (b)(529.93), which read: “Reserved;”, deleted paragraph (b)(703.43), which read: “Reserved;”, deleted paragraph (b)(731.1), which read: “Reserved;”, deleted paragraph (b)(732.9), which read: “Reserved;”, substituted “Respiratory syncytial virus vaccine” for “Respiratory Syncytial Virus Vaccine” in paragraph (b)(836.1), deleted paragraph (b)(851.02), which read: “Reserved;”, substituted “Sermorelin acetate” for “Sermorelin Acetate” in paragraph (b)(855.5), deleted paragraph (b)(945.5), which read: “Reserved;”, substituted “Varicella virus vaccine, Live” for “Varicella Virus Vaccine Live” in paragraph (b)(1025.8), substituted “Von Willebrand factor” for “von Willebrand factor” in paragraph (b)(1037.23), substituted “Zoledronic acid” for “Zoledronic Acid” in paragraph (b)(1042.8), and substituted “Zoster vaccine recombinant, Adjuvanted” for “Zoster Vaccine Recombinant, Adjuvanted” in paragraph (b)(1042.95); and, in paragraph (c)(16.92), substituted a semicolon for a period at the end.

ARTICLE 6

KRATOM

16-13-122. Content of kratom; required labeling.

(a) All kratom products sold in, or delivered to, this state shall be derived from the natural kratom plant, and any manufactured or processed kratom product, including kratom extracts, shall not be modified, chemically or otherwise, processed, synthesized, or otherwise treated in any way that increases the levels of mitragynine or 7-hydroxymitragynine, beyond those described in subsection (b) of this Code section.

(b) No kratom product sold in, or delivered to, this state shall have a concentration ratio that is:

- (1) Greater than 150 mg mitragynine per serving;
- (2) Greater than 0.5 mg 7-hydroxymitragynine per gram; or
- (3) Greater than 1 mg 7-hydroxymitragynine per serving.

(c) A processor or retailer shall not prepare, distribute, sell, or expose for sale any of the following:

- (1) A kratom product that is adulterated;
 - (2) A kratom product that contains or uses in its processing or manufacturing a food substance that is not generally recognized as safe in food products;
 - (3) A kratom product containing any synthetic alkaloids or metabolite including synthetic mitragynine, synthetic 7-hydroxymitragynine, or any other synthetically derived compounds of the kratom plant; or
 - (4) A kratom product in a form that employs a heating element, power source, electronic circuit, or other electronic, chemical, or mechanical means, regardless of shape or size, that can be used to produce vapor in a solution or other form, including, but not limited to, any electronic cigarette, electronic cigar, electronic cigarillo, electronic pipe, or similar product or device and any vapor cartridge or other container of kratom in a solution or other form that is intended to be used with or in an electronic cigarette, electronic cigar, electronic cigarillo, electronic pipe, or similar product or device.
- (d) A processor shall maintain a registered agent in this state for service of process for the entire duration of such entity's engagement in the business of a processor.
- (e) Kratom packaging shall be accompanied by a label bearing the following information prior to its sale in this state:
- (1) Clearly labeled ingredients;
 - (2) That the sale or transfer possession of kratom to another person under 21 years of age is prohibited;
 - (3) The amount of mitragynine and 7-hydroxymitragynine contained in such product;
 - (4) The total amount of mitragynine and 7-hydroxymitragynine contained in the packaging for such product;
 - (5) The common or usual name of each ingredient used in the manufacture of such product, listed in descending order of predominance;
 - (6) The name, physical address, and principal mailing address of the manufacturer or the person responsible for distributing such product;
 - (7) Clear and adequate directions for the consumption of such product, including the recommended serving size and the time frame within which safe consumption should occur;
 - (8) Any precautionary statements as to the safety and effectiveness of such product, including a warning that a consumer should

consult their physician on questions about use of kratom, and state that the kratom product is not intended to “diagnose, treat, cure or prevent any disease”; and

(9) A statement that a kratom product label is prohibited from making any therapeutic claims unless approved by the United States Food and Drug Administration.

(f)(1) A processor who knowingly or with criminal negligence commits an act in violation of this Code section shall, upon a first conviction thereof, be guilty of a misdemeanor of a high and aggravated nature, and upon a subsequent conviction, be guilty of a felony, and shall be punished by imprisonment for not less than one year nor more than 15 years, by a fine not to exceed \$100,000.00, or both.

(2) A processor who negligently commits an act in violation of this Code section shall be guilty of a misdemeanor and subject to a fine not to exceed \$1,000.00.

(g)(1) A retailer who knowingly or with criminal negligence commits an act in violation of subsection (a), (b), (c), or (e) of this Code section shall, upon a first conviction thereof, be guilty of a misdemeanor of a high and aggravated nature, and upon a subsequent conviction, be guilty of a felony, and shall be punished by imprisonment for not less than one year nor more than 15 years, by a fine not to exceed \$100,000.00, or both.

(2) A retailer who negligently commits an act in violation of subsection (a), (b), (c), or (e) of this Code section shall be guilty of a misdemeanor; provided, however, that, for a conviction of a first offense, such individual shall be punished by a fine not to exceed \$250.00; for a conviction of a second offense, such individual shall be punished by a fine of up to \$500.00; and for a conviction of a third offense, such individual shall be punished by a fine of up to \$1,000.00; provided, further, that upon each subsequent conviction after a third conviction, such individual shall be guilty of a high and aggravated misdemeanor and shall be imprisoned for not less than ten days nor more than 12 months and punished by a fine of not less than \$1,000.00 nor more than \$5,000.00.

(3) A retailer shall have a defense to prosecution under this subsection if such retailer proves by a preponderance of the evidence that the retailer relied in good faith upon the representations of a processor that the kratom, kratom product, or kratom extract and labeling complied with the provisions of this Code section.

History.

Code 1981, § 16-13-122, enacted by Ga. L. 2019, p. 273, § 1/HB 551; Ga. L. 2024, p. 544, § 3/HB 181, effective January 1, 2025; Ga. L. 2025, p. 1029, § 16(11)/SB 153, effective July 1, 2025.

Amendments.

The 2025 amendment, effective July 1, 2025, part of an Act to revise, modern-

ize, and correct the Code, deleted “of” following “150 mg” in paragraph (b)(1).

CHAPTER 14

RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS

Sec.

16-14-3. Definitions.

16-14-3. Definitions.

As used in this chapter, the term:

(1) “Civil forfeiture proceeding” shall have the same meaning as set forth in Code Section 9-16-2.

(2) “Criminal proceeding” means any criminal proceeding commenced by the Department of Law or the office of any district attorney under any provision of this chapter.

(3) “Enterprise” means any person, sole proprietorship, partnership, corporation, business trust, union chartered under the laws of this state, or other legal entity; or any unchartered union, association, or group of individuals associated in fact although not a legal entity; and it includes illicit as well as licit enterprises and governmental as well as other entities.

(4) “Pattern of racketeering activity” means:

(A) Engaging in at least two acts of racketeering activity in furtherance of one or more incidents, schemes, or transactions that have the same or similar intents, results, accomplices, victims, or methods of commission or otherwise are interrelated by distinguishing characteristics and are not isolated incidents, provided at least one of such acts occurred after July 1, 1980, and that the last of such acts occurred within four years, excluding any periods of imprisonment, after the commission of a prior act of racketeering activity; or

(B) Engaging in any one or more acts of domestic terrorism as described in Code Section 16-11-221 or any criminal attempt, criminal solicitation, or criminal conspiracy related thereto.

(5)(A) “Racketeering activity” means to commit, to attempt to commit, or to solicit, coerce, or intimidate another person to commit any crime which is chargeable by indictment under the laws of this state involving:

- (i) Unlawful distillation, manufacture, and transportation of alcoholic beverages in violation of Code Section 3-3-27;
- (ii) Records and reports of currency transactions in violation of Article 11 of Chapter 1 of Title 7;
- (iii) The “Georgia Uniform Securities Act of 2008” in violation of Chapter 5 of Title 10;
- (iv) Homicide in violation of Article 1 of Chapter 5 of this title;
- (v) Assault and battery in violation of Article 2 of Chapter 5 of this title;
- (vi) Kidnapping, false imprisonment, and related offenses in violation of Article 3 of Chapter 5 of this title;
- (vii) Prostitution, keeping a place of prostitution, pimping, and pandering in violation of Code Sections 16-6-9 through 16-6-12;
- (viii) Burglary in violation of Code Section 16-7-1;
- (ix) Smash and grab burglary in violation of Code Section 16-7-2;
- (x) Arson and explosives in violation of Article 3 of Chapter 7 of this title;
- (xi) Bombs, explosives, and chemical and biological weapons in violation of Article 4 of Chapter 7 of this title;
- (xii) Theft in violation of Article 1 of Chapter 8 of this title;
- (xiii) Robbery in violation of Article 2 of Chapter 8 of this title;
- (xiv) Criminal reproduction and sale of recorded material in violation of Article 3 of Chapter 8 of this title;
- (xv) The “Georgia Residential Mortgage Fraud Act” in violation of Article 5 of Chapter 8 of this title;
- (xvi) Forgery in any degree in violation of Code Section 16-9-1;
- (xvii) Illegal use of financial transaction cards in violation of Code Sections 16-9-31, 16-9-32, 16-9-33, and 16-9-34;
- (xviii) Use of an article with an altered identification mark in violation of Code Section 16-9-70;
- (xix) The “Georgia Computer Systems Protection Act” in violation of Article 6 of Chapter 9 of this title;
- (xx) Identity fraud in violation of Article 8 of Chapter 9 of this title;

- (xxi) Bribery in violation of Code Section 16-10-2;
- (xxii) False statements and writings or false lien statements against public officers or public employees in violation of Code Section 16-10-20 or 16-10-20.1;
- (xxiii) Impersonating a public officer or employee in violation of Code Section 16-10-23;
- (xxiv) Attempted murder or threatening of witnesses in official proceedings in violation of Code Section 16-10-32;
- (xxv) Perjury and other related offenses in violation of Article 4 of Chapter 10 of this title;
- (xxvi) Embracery in violation of Code Section 16-10-91;
- (xxvii) Influencing witnesses in violation of Code Section 16-10-93;
- (xxviii) Tampering with evidence in violation of Code Section 16-10-94;
- (xxix) Intimidation or injury of grand or trial juror or court officer in violation of Code Section 16-10-97;
- (xxx) Terroristic threats and acts in violation of Code Section 16-11-37;
- (xxxi) The “Georgia Firearms and Weapons Act” in violation of Part 2 of Article 4 of Chapter 11 of this title;
- (xxxii) Commercial gambling in violation of Code Section 16-12-22;
- (xxxiii) Distributing obscene materials in violation of Code Section 16-12-80;
- (xxxiv) The “Georgia Controlled Substances Act” in violation of Article 2 of Chapter 13 of this title;
- (xxxv) The “Dangerous Drug Act” in violation of Article 3 of Chapter 13 of this title;
- (xxxvi) Marijuana in violation of subsection (j) of Code Section 16-13-30;
- (xxxvii) Payday loans in violation of Chapter 17 of this title;
- (xxxviii) Insurance fraud in violation of Code Section 33-1-9;
- (xxxix) Certain felonies involving certificates of title, security interest, or liens in violation of Code Section 40-3-90;

(xl) Removal or falsification of identification numbers in violation of Code Section 40-4-21;

(xli) Possession of motor vehicle parts from which the identification has been removed in violation of Code Section 40-4-22;

(xlii) Article 8 of Chapter 5 of this title, relating to protection of elder persons; or

(xliii) Offenses enumerated in Code Section 16-12-37.

(B) “Racketeering activity” shall also mean any act or threat involving murder, kidnapping, gambling, arson, robbery, theft, receipt of stolen property, bribery, extortion, obstruction of justice, dealing in narcotic or dangerous drugs, or dealing in securities which is chargeable under the laws of the United States, any territory of the United States, or any state and which is punishable by imprisonment for more than one year.

(C) “Racketeering activity” shall also mean any conduct defined as “racketeering activity” under 18 U.S.C. Section 1961 (1), any violation of 18 U.S.C. Section 1028, or any violation of 31 U.S.C. Sections 5311 through 5330.

(6) “Real property” means any real property situated in this state or any interest in such real property, including, but not limited to, any lease of or mortgage upon such real property.

History.

Code 1933, § 26-3402, enacted by Ga. L. 1980, p. 405, § 1; Ga. L. 1982, p. 1385, §§ 2, 8; Ga. L. 1983, p. 3, § 13; Ga. L. 1984, p. 22, § 16; Ga. L. 1989, p. 14, § 16; Ga. L. 1990, p. 8, § 16; Ga. L. 1994, p. 1625, § 4; Ga. L. 1996, p. 416, § 8; Ga. L. 1998, p. 128, § 16; Ga. L. 1998, p. 270, § 7; Ga. L. 1999, p. 81, § 16; Ga. L. 2001, p. 858, § 1; Ga. L. 2002, p. 551, § 3; Ga. L. 2002, p. 1284, § 3; Ga. L. 2003, p. 387, § 1; Ga. L. 2004, p. 60, § 2; Ga. L. 2004, p. 161, § 4; Ga. L. 2005, p. 199, § 5/SB 62; Ga. L. 2005, p. 848, § 3/SB 100; Ga. L. 2006, p. 69, § 2/HB 804; Ga. L. 2008, p. 381, § 9/SB 358; Ga. L. 2010, p. 1147, § 8/HB 1104; Ga. L. 2011, p. 59, § 1-64/HB 415; Ga. L. 2011, p. 752, § 16/HB

142; Ga. L. 2012, p. 90, § 2/HB 997; Ga. L. 2012, p. 637, § 2/HB 1114; Ga. L. 2012, p. 899, § 8-6/HB 1176; Ga. L. 2015, p. 5, § 16/HB 90; Ga. L. 2015, p. 598, § 1-4/HB 72; Ga. L. 2015, p. 693, § 2-25/HB 233; Ga. L. 2019, p. 74, § 2-5/SB 158; Ga. L. 2020, p. 493, § 16/SB 429; Ga. L. 2023, p. 302, § 1/SB 68, effective July 1, 2023; Ga. L. 2024, p. 1052, § 3(17)/SB 448, effective July 1, 2024; Ga. L. 2025, p. 224, § 2-3/HB 161, effective July 1, 2025.

Amendments.

The 2025 amendment, effective July 1, 2025, substituted “described in Code Section 16-11-221” for “described in paragraph (2) of Code Section 16-11-220” in subparagraph (4)(B).

16-14-4. Prohibited activities.

JUDICIAL DECISIONS

ANALYSIS

APPLICATION

2. COMPANIES AND EMPLOYEES

Application

2. Companies and Employees

Civil complaint against company failed to state RICO violation. —

Plaintiffs failed to show that their injuries flowed directly from the alleged predicate acts of defendant, a brokerage and investment bank, as required to establish proximate cause for a RICO claim, because plaintiffs’ injuries were, at best, an

indirect result of defendant’s alleged facilitation or coverup of a Ponzi scheme by a person associated with defendant. The alleged violations of the Georgia Uniform Securities Act all occurred before December 2016, at which point all of the scheme-related accounts had been transferred out of defendant and the person had already resigned. *Kearny v. Oppenheimer & Co.*, 375 Ga. App. 254, 2025 Ga. App. LEXIS 177 (2025).

CHAPTER 15

STREET GANG TERRORISM AND PREVENTION

16-15-3. Definitions.

JUDICIAL DECISIONS

Evidence of gang association.

Revocation of defendant’s probation was remanded for reconsideration as the state failed to show a nexus between defendant’s activities and gang activity as required under the Street Gang Terrorism and Prevention Act, O.C.G.A. § 16-15-1 et seq. *Alexander v. State*, 371 Ga. App. 532, 901 S.E.2d 584, 2024 Ga. App. LEXIS 181 (2024).

Evidence presented at trial was sufficient to establish that Yung Fame was a

gang for purposes of the Street Gang and Terrorism Prevention Act, O.C.G.A. § 16-15-1 et seq., and that the defendant was associated with the gang as the state presented sufficient evidence to establish that Yung Fame was a group of three or more persons that conspired to engage in “criminal gang activity” and that the defendant was associated with Yung Fame. *Tedder v. State*, 320 Ga. 29, 907 S.E.2d 623, 2024 Ga. LEXIS 230 (2024).

16-15-4. Participation in criminal gang activity prohibited; prosecution.

JUDICIAL DECISIONS

ANALYSIS

GENERAL CONSIDERATION
APPLICATION

General Consideration

Jury instructions. — Trial court did not err in instructing the jury on the elements of participation in criminal street gang activity because the instruction largely tracked the pattern jury instructions for the offense, the trial court unequivocally instructed the jury that the state needed to show a nexus or connection between defendant's crimes and the gang, and when the jury instructions were considered as a whole it was apparent that the trial court did not authorize the jury to find defendant guilty simply because defendant committed a category of crime that members of the gang were known to commit. *Lee v. State*, 374 Ga. App. 329, 912 S.E.2d 700, 2025 Ga. App. LEXIS 49 (2025).

Application

Evidence of connection to gang.

Revocation of defendant's probation was remanded for reconsideration as the state failed to show a nexus between defendant's activities and gang activity as required under the Street Gang Terrorism and Prevention Act, O.C.G.A. § 16-15-1 et seq. *Alexander v. State*, 371 Ga. App. 532, 901 S.E.2d 584, 2024 Ga. App. LEXIS 181 (2024).

Evidence was sufficient to support appellant's Street Gang and Terrorism Prevention Act, O.C.G.A. § 16-15-1 et seq., violation as the evidence presented demonstrated appellant was a high-ranking gang member who committed the crimes to further the gang's interests, and the gang expert's testimony was properly admitted as relevant to the charges, and any risk of unfair prejudice did not substantially outweigh its probative value. *Pierce v. State*, 319 Ga. 846, 907 S.E.2d 281, 2024 Ga. LEXIS 212 (2024).

Evidence was sufficient to support the defendant's conviction under the Street Gang Terrorism and Prevention Act,

O.C.G.A. § 16-15-1 et seq., because the evidence showed that the defendant was associated with the gang even though the defendant was not a member and that defendant committed the aggravated assault with a deadly weapon. *Rosenau v. State*, 321 Ga. 299, 914 S.E.2d 300, 2025 Ga. LEXIS 65 (2025).

Evidence sufficient to show party to gang activity.

Evidence that the Gangster Disciples was a criminal street gang and that the defendant and others from the gang participated in the beating of the victim was sufficient to support the conviction for violation of the Georgia Street Gang Terrorism and Prevention Act, O.C.G.A. § 16-15-1 et seq. *Dupree v. State*, 374 Ga. App. 421, 913 S.E.2d 41, 2025 Ga. App. LEXIS 65 (2025).

Evidence sufficient for conviction.

Evidence was sufficient to support defendant's convictions of malice murder, conspiracy to murder, possession of a firearm during the commission of a felony, and violation of the Street Gang Terrorism and Prevention Act, O.C.G.A. § 16-15-1 et seq., because there was eye witness testimony that defendant and a co-defendant drove to the victim's apartment, called them to the car, and defendants shot the victims. The evidence also showed defendant was a high-ranking gang member. *Campbell v. State*, 320 Ga. 333, 907 S.E.2d 871, 2024 Ga. LEXIS 247 (2024).

Evidence of gang activity.

Trial court did not err by admitting evidence of defendant's gang membership because he was charged with eight counts of violating the Street Gang Terrorism and Prevention Act, O.C.G.A. § 16-15-1, et seq., the state was required to prove that defendant was associated with a particular street gang, and therefore evidence proving his membership in the gang was relevant. *Campbell v. State*, 320 Ga. 333, 907 S.E.2d 871, 2024 Ga. LEXIS 247 (2024).

16-15-9. Commission of offense admissible as evidence of existence of criminal street gang.**JUDICIAL DECISIONS****Evidence sufficient for conviction.**

Evidence was sufficient to support appellant's Street Gang and Terrorism Prevention Act, O.C.G.A. § 16-15-1 et seq., violation as the evidence presented demonstrated appellant was a high-ranking gang member who committed the crimes to further the

gang's interests, and the gang expert's testimony was properly admitted as relevant to the charges, and any risk of unfair prejudice did not substantially outweigh its probative value. *Pierce v. State*, 319 Ga. 846, 907 S.E.2d 281, 2024 Ga. LEXIS 212 (2024).

